Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Ohio
Clinical trial register · United States · industry-sponsored

Clinical Trials in Ohio, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9118 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 06 Oct 2026, 03:16 UTC
9118
Studies in scope
industry-sponsored, all four open statuses
4945
Recruiting now
open to new participants
2189
Lead sponsors
across recruiting studies
Top states
California 5290 Florida 4430 Illinois 2481 Georgia 2368 Arizona 2238
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca36 Novartis Pharmaceuticals28 Hoffmann-La Roche25 Merck Sharp & Dohme LLC20 GlaxoSmithKline19
State
California5290 Florida4430 Illinois2481 Georgia2368 Arizona2238
All 51 states
Target enrolment
to

Trials with a site in Ohio

1263 of 9118 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
Pro-2-Cool Pivotal Trial II
NCT06929923Concussion, Mild
TecTraum Inc.
Not applicable
66
Michigan, Ohio
2025-02-20
Recruiting
Feasibility Study of CBCT for IGRT in Cancer Patients
NCT06681233Head and Neck Cancers, Breast Cancer, Thoracic Cancers, Liver Cancer
Varian, a Siemens Healthineers Company
Not applicable
50
Ohio
2025-02-19
Recruiting
Sensing Physiological Symptoms of Opioid Withdrawal and Cravings in Patients With Opioid Use Disorder
NCT06487533Opioid Withdrawal, Opioid Use Disorder
Spark Biomedical, Inc.
Observational
20
Minnesota, Ohio
2025-02-19
Recruiting
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
NCT06760819Advanced Solid Tumors, HER2 Mutation
DrugSevabertinib
Bayer
Phase 2
111
Alabama, California, Florida, Massachusetts, Michigan, Ohio, Tennessee, Texas
2025-02-13
Recruiting
MOTION Clinical Trial
NCT06843980Osteoarthritis, Knee
Moximed
Not applicable
100
California, Illinois, Nebraska, New York, Ohio, Texas
2025-02-13
Recruiting
EEG-based Personalized Transcranial Magnetic Stimulation (eTMS) to Treat Post-Traumatic Stress Disorder
NCT06892028Stress Disorder, Post Traumatic
Wave Neuroscience
Not applicable
110
Ohio
2025-02-12
Recruiting
A Study of TAK-360 in Adults With Idiopathic Hypersomnia
NCT06812078Idiopathic Hypersomnia
DrugTAK-360
Takeda
Phase 2
96
California, Colorado, Florida, Missouri, North Carolina, Ohio, South Carolina, Texas
2025-02-07
Active, closed
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
NCT06834360Chronic Rhinosinusitis With Nasal Polyps
DrugsItepekimab·Mometasone furoate
Sanofi
Phase 3
216
Alabama, California, Florida, Illinois, Kentucky, Louisiana, Maryland, Ohio
2025-02-06
Active, closed
Pivotal Clinical Trial Evaluating the Safety and Efficacy of the Fully Implanted Acclaim Cochlear Implant
NCT06699797Sensori-Neural Deafness, Sensorineural Hearing Loss, Sensorineural Hearing Loss (Disorder), Sensorineural Hearing Loss, Bilateral
Envoy Medical Corporation
Not applicable
56
Arizona, California, Florida, Minnesota, Ohio, Oklahoma, South Carolina
2025-02-06
Recruiting
North American Comfilcon A Clinical Study
NCT06902584Astigmatism, Presbyopia, Ametropia
CooperVision International Limited (CVIL)
Observational
182
California, Ohio, Pennsylvania, Texas
2025-02-05
Recruiting
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
NCT06618287Lung Cancer, Breast Cancer
DrugsPumitamig·Iza-bren·Osimertinib·Opdivo
Bristol-Myers Squibb
Phase 1/2
416
Alabama, Florida, Iowa, Missouri, New Jersey, Ohio, Oregon, Pennsylvania
2025-02-04
By invitation
Mental Health, Intellectual and Neurodevelopmental Disorder Detection With Artificial Intelligence Models
NCT06792175Autism Spectrum Disorder, Depression - Major Depressive Disorder, Anxiety, Generalized, Bipolar Disorder (BD)
Psyrin Inc.
Observational
500
Massachusetts, Ohio
2025-02-04
Recruiting
Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure
NCT06651970Chronic Lymphocytic Leukaemia, Moderate to Severe Cardiac Impairment
DrugAcalabrutinib
AstraZeneca
Phase 4
60
North Carolina, Ohio, Pennsylvania
2025-02-04
Recruiting
A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
NCT06720987KRAS G12C Mutation, KRAS G12S Mutation, Solid Tumor Malignancies, CRC (Colorectal Cancer)
DrugsKQB198·Cetuximab
Kumquat Biosciences Inc.
Phase 1
140
Arizona, Colorado, Florida, Massachusetts, Michigan, Minnesota, Ohio, Oklahoma
2025-02-04
Recruiting
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
NCT06805825Gastrointestinal Stromal Tumors, Small-cell Lung Cancer, Adenoid Cystic Carcinoma, Uveal Melanoma
Novelty Nobility, Inc.
Phase 1
67
Michigan, Ohio, Oregon, Texas, Virginia
2025-02-03
Recruiting
Study of Olutasidenib and Temozolomide in HGG
NCT06161974High Grade Glioma, Astrocytoma, Astrocytoma, Grade III, Astrocytoma, Grade IV
DrugOlutasidenib
Rigel Pharmaceuticals
Phase 2
60
Colorado, District of Columbia, Florida, Illinois, Massachusetts, North Carolina, Ohio, Pennsylvania
2025-02-01
Recruiting
Pediatric Down Syndrome Post-Approval Study
NCT06851338Pediatric Obstructive Sleep Apnea, Down Syndrome (DS)
Inspire Medical Systems, Inc.
Not applicable
60
Arizona, California, Florida, New York, Ohio, Texas
2025-02
Recruiting
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
NCT06514794T-cell Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
Allotera Therapeutics
Phase 2
125
California, Colorado, District of Columbia, Florida, Georgia, Missouri, New York, Ohio
2025-01-31
Recruiting
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
NCT06564038Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma, Large B-cell Lymphoma
DrugsSurovatamig·Acalabrutinib·Vincristine·Doxorubicin
AstraZeneca
Phase 1/2
408
Massachusetts, New Jersey, New York, North Carolina, Ohio, Oregon, Pennsylvania, Rhode Island
2025-01-30
Active, closed
A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)
NCT06809595Generalized Anxiety Disorder
DrugDT120
Definium Therapeutics US, Inc.
Phase 3
245
Arkansas, California, Florida, Georgia, Maryland, Massachusetts, New Jersey, Ohio
2025-01-29
Recruiting
An Open-Label Pilot Study of VTX2735 in Recurrent Pericarditis
NCT06836232Recurrent Pericarditis
Zomagen Biosciences Ltd.
Phase 2
50
California, Florida, Illinois, Massachusetts, Minnesota, New York, Ohio, Texas
2025-01-28
Recruiting
Clinical Outcome Measure at Stryker Spine
NCT06226272Degenerative Disc Disease, Degenerative Scoliosis
VB Spine, LLC
Observational
5,222
Florida, Maine, Michigan, Ohio, Tennessee, Texas
2025-01-28
Active, closed
A Study of SHJ002 Sterile Ophthalmic Solution for Myopia Control
NCT06579287Myopia, Progressive
DrugAtropine
Sunhawk Vision Biotech, Inc.
Phase 2
140
Ohio
2025-01-22
Recruiting
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
NCT06100289Ulcerative Colitis, Crohn's Disease
DrugVedolizumab
Takeda
Phase 3
70
Arizona, California, Illinois, Michigan, New Jersey, New York, Ohio, Oklahoma
2025-01-22
Recruiting
Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NCT06786624Major Depressive Disorder
DrugNBI-1065845
Neurocrine Biosciences
Phase 3
200
Arkansas, California, Florida, Massachusetts, New York, Ohio, Texas, Washington
2025-01-22
Active, closed
A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors
NCT06777316Intrahepatic Cholangiocarcinoma (Icc), Cholangiocarcinoma, Other Solid Tumors, Adult, FGFR2 Gene Fusion/Rearrangement
Cogent Biosciences, Inc.
Phase 1/2
110
California, Florida, Illinois, Massachusetts, Minnesota, Ohio, Pennsylvania, Tennessee
2025-01-22
Active, closed
Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)
NCT06632951Urothelial Carcinoma
DrugsLivmoniplimab·Budigalimab·Docetaxel·Gemcitabine
AbbVie
Phase 2
150
Arkansas, California, Connecticut, Delaware, Florida, New York, Ohio, Tennessee
2025-01-20
Recruiting
Sirolimus Coated BALloon Versus Standard Balloon Angioplasty in The Treatment of Below The Knee Arterial Disease
NCT06182397Arterial Disease of Legs, Below-the-knee Obstruction, PAD - Peripheral Arterial Disease
Concept Medical Inc.
Not applicable
368
Arizona, California, Florida, Iowa, Michigan, New Jersey, New York, Ohio
2025-01-16
Active, closed
HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE)
NCT06634420Hereditary Angioedema
Intellia Therapeutics
Phase 3
80
Arizona, California, Colorado, Florida, Massachusetts, Missouri, New York, Ohio
2025-01-15
Recruiting
A Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder
NCT06809179Social Anxiety Disorder
VistaGen Therapeutics, Inc.
Phase 2
60
California, Florida, Missouri, New Jersey, North Carolina, Ohio, Pennsylvania, Texas
2025-01-09
Recruiting
Dose Escalation Study of EG110A, Administered by Intradetrusor Injections to Adults With Neurogenic Detrusor Overactivity-related Incontinence Following Spinal Cord Injury Who Regularly Perform Clean Intermittent Catheterization
NCT06596291Neurogenic Detrusor Overactivity, Spinal Cord Injuries
DrugEG110A
Cyllene Therapeutics
Phase 1/2
16
California, Michigan, Ohio, Pennsylvania, Texas
2025-01-08
Recruiting
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
NCT06774963Ovarian Cancer, Breast Cancer, Endometrial Cancer, Biliary Tract Cancer
NextCure, Inc.
Phase 1
145
California, Kentucky, Massachusetts, Missouri, New Jersey, New York, Ohio, Pennsylvania
2025-01-07
Active, closed
Safety and Efficacy of a Drug Eluting Slim Modiolar Electrode Array
NCT06598059Hearing Loss
DrugDexamethasone
Cochlear
Not applicable
56
California, Colorado, Iowa, Michigan, Missouri, New York, Ohio, Oregon
2025-01-03
Recruiting
Study of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors
NCT06566079Malignant Mesothelioma, Metastatic Malignant Solid Tumor, Advanced Solid Tumor
InSilico Medicine Hong Kong Limited
Phase 1/2
160
Colorado, Illinois, Ohio, Pennsylvania, Tennessee, Texas
2024-12-27
Active, closed
A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformations
NCT06653842Cutaneous Venous Malformations
DrugQTORIN rapamycin anhydrous
Palvella Therapeutics, Inc.
Phase 2
15
California, Colorado, Maryland, Minnesota, North Carolina, Ohio, Pennsylvania, Utah
2024-12-20
Recruiting
A Study to Assess the Incidence of Skin Cancers in Patients With Epidermolysis Bullosa Receiving Filsuvez
NCT06423573Epidermolysis Bullosa, Dystrophic, Epidermolysis Bullosa, Junctional
Chiesi Farmaceutici S.p.A.
Observational
170
California, Colorado, Florida, Ohio, Pennsylvania, South Carolina
2024-12-18
Recruiting
Suprachoroidal Administration in Subjects With Metastases to the Choroid
NCT06643884Eye Cancer, Primary Cancer
DrugBel-sar
Aura Biosciences
Phase 2
24
California, Florida, Massachusetts, Michigan, Minnesota, Ohio, Pennsylvania, Tennessee
2024-12-16
Recruiting
The PERSEVERE Study
NCT06588634Pulmonary Embolism, Pulmonary Thromboembolism
Inari Medical
Not applicable
200
Connecticut, Florida, Georgia, Mississippi, New York, Ohio, Pennsylvania, Tennessee
2024-12-16
Recruiting
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
NCT06784193Advanced or Metastatic ER+ HER2- Breast Cancer (mBC), Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC), Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC), Metastatic Breast Cancer
DrugsPalazestrant·Fulvestrant
Olema Pharmaceuticals, Inc.
Phase 1
180
Arizona, Colorado, Florida, Louisiana, Massachusetts, Michigan, New York, Ohio
2024-12-16
Recruiting
Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment
NCT06274788Parenteral Nutrition Associated Liver Disease (PNALD), Essential Fatty Acid Deficiency, Malnutrition, Pediatric ALL
Fresenius Kabi
Observational
40
California, Illinois, Massachusetts, Ohio, Oklahoma, Tennessee, Texas, Washington
2024-12-15
Active, closed
PMN310 in Patients With Early Alzheimer's Disease (PRECISE-AD)
NCT06750432Alzheimer Disease, Early Onset
ProMis Neurosciences, Inc
Phase 1
144
California, Florida, Georgia, Massachusetts, New Jersey, New York, North Carolina, Ohio
2024-12-13
Recruiting
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
NCT06657222Advanced Solid Tumors, HNSCC, SCLC, NSCLC
Gilead Sciences
Phase 1/2
250
Connecticut, Florida, Massachusetts, Minnesota, Missouri, New York, Ohio, Texas
2024-12-13
Recruiting
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer
NCT06463028Endometrial Cancer
DrugsSerabelisib·Sapanisertib·Paclitaxel
Faeth Therapeutics
Phase 2
40
California, Florida, Maryland, Minnesota, New York, Ohio, Oregon, Pennsylvania
2024-12-12
Active, closed
A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic Malignancies
NCT06645886Hematologic Malignancies, Adult
DrugsKQB198·Dasatinib
Kumquat Biosciences Inc.
Phase 1
13
California, Colorado, Florida, Michigan, North Carolina, Ohio, Tennessee, Texas
2024-12-09
Recruiting
A Study to Evaluate Safety, Tolerability, and Immunogenicity of V350A and V350B in Healthy Participants (V350-001).
NCT06655324Healthy
Merck Sharp & Dohme LLC
Phase 1
250
California, Florida, Missouri, Nebraska, Ohio, Oklahoma, Tennessee
2024-12-05
Recruiting
A Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic Arthritis
NCT06454188Psoriatic Arthritis, Spondyloarthritis, Axial
DrugUpadacitinib
CARE ARTHRITIS LTD.
Phase 4
100
Ohio, Oregon, Pennsylvania
2024-12-03
Recruiting
Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer
NCT06613100Prostate Cancer
DrugXaluritamig
Amgen
Phase 1
40
California, Missouri, Ohio, Pennsylvania, South Carolina, Washington, Wisconsin
2024-11-25
Active, closed
Retrospective Acute Care Appendectomy Study
NCT06624215Acute Appendicitis
Intuitive Surgical
Observational
1,000
Ohio, Oregon, Texas
2024-11-22
Recruiting
Acellular Dermal Matrix Investigation in Breast Reconstruction
NCT06456554Breast Reconstruction
RTI Surgical
Not applicable
467
Arkansas, California, Colorado, Kansas, Missouri, New York, Ohio, Oklahoma
2024-11-22
Active, closed
A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)
NCT06698042Lung Cancer, Non-Small Cell Lung Cancer
Drugs) Berahyaluronidase alfa·Keytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
67
California, Illinois, New York, Ohio
2024-11-21
Recruiting
A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer
NCT06678659Unresectable, Locally Advanced, Metastatic Cancers, Relapsed/Refractory Lymphomas
Recursion Pharmaceuticals Inc.
Phase 1/2
170
California, Ohio, Tennessee, Utah
2024-11-21
Recruiting
A Single-arm, Pivotal Study to Evaluate Acute Device and Technical Success of the CGuard Prime Carotid Stent System When Used in Conjunction to the ENROUTE Transcarotid Neuroprotection System in Patients Undergoing Carotid Artery Stenting Via the Transcarotid Artery Revascularization Approach
NCT06653387Carotid Artery Diseases
InspireMD
Not applicable
50
California, Indiana, Minnesota, Missouri, Montana, New York, Ohio
2024-11-20
Active, closed
Avalus Ultra Post-Approval Study (PAS)
NCT06506903Aortic Valve Disease
Medtronic Cardiac Surgery
Not applicable
190
Connecticut, Florida, Georgia, Illinois, Michigan, Minnesota, New York, Ohio
2024-11-20
Active, closed
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
NCT06465329Non-Small Cell Lung Cancer
DrugsMarlotamig·Cemiplimab
Regeneron Pharmaceuticals
Phase 2
120
California, Illinois, Michigan, Ohio, Oregon, Rhode Island, South Dakota, Tennessee
2024-11-18
Recruiting
Rising Tide - Amniotic Tissue(s) Treatments for Chronic Diabetic Foot Ulcers
NCT06681428Diabetic Foot Ulcer (DFU), Chronic Foot Ulcers
Tides Medical
Not applicable
240
California, Florida, North Carolina, Ohio, Virginia
2024-11-14
Recruiting
A Study Evaluating the Safety and Efficacy of PRV111, PRV211, and PRV131 in Subjects With Oral and Lung Cancers
NCT05893888Oral Squamous Cell Carcinoma
DrugCisplatin
Privo Technologies
Phase 2/3
40
California, Florida, Illinois, Ohio
2024-11-07
By invitation
Non-invasive Rejuvenation of the Periorbital Area and Lower Eyelid
NCT07028203Periorbital Wrinkles, Periorbital Area, Under-eyes Dark Circles, Crows Feet
BTL Industries Ltd.
Not applicable
30
California, Ohio
2024-11-05
Recruiting
Glycogen Storage Disease Type Ia (GSDIa) Disease Monitoring Program
NCT06636383Glycogen Storage Disease Type Ia
Ultragenyx Pharmaceutical Inc
Observational
140
California, Colorado, Connecticut, Michigan, North Carolina, Ohio, Pennsylvania, Texas
2024-11-04
Recruiting
A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer
NCT06457503Nasopharyngeal Cancer Recurrent
DrugsJS001·Toripalimab·Gemcitabine·Cisplatin
Coherus Oncology, Inc.
Phase 4
100
Arkansas, California, Georgia, Massachusetts, Michigan, New York, Ohio, Pennsylvania
2024-11-01
Active, closed
Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With Hypoparathyroidism
NCT06531941Hypoparathyroidism
MBX Biosciences
Phase 2
60
Florida, Georgia, Mississippi, Missouri, Nevada, New York, Ohio, Texas
2024-10-31
Recruiting
Barrigel® PPRT (Post-Prostatectomy Radiation Therapy) Trial
NCT06496256Prostate Cancer
Palette Life Sciences, Inc.
Not applicable
84
Arizona, California, Florida, Georgia, Massachusetts, New Jersey, Ohio, Pennsylvania
2024-10-31
Active, closed
A Study of ZW191 in Participants With Solid Tumors
NCT06555744Advanced Solid Tumors
Zymeworks BC Inc.
Phase 1
145
Connecticut, Ohio, Oklahoma, Texas, Virginia
2024-10-30
Active, closed
SpaceIT Hydrogel System for Perirectal Spacing
NCT06451614Prostate Cancer
Boston Scientific Corporation
Not applicable
230
California, Florida, Georgia, Illinois, Kansas, New York, Ohio, Pennsylvania
2024-10-30
Active, closed
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis
NCT06655896Scleroderma, Diffuse
DrugsRapcabtagene autoleucel·Rituximab
Novartis Pharmaceuticals
Phase 2
96
California, Florida, Illinois, Iowa, Massachusetts, Michigan, Minnesota, Ohio
2024-10-29
Recruiting
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
NCT06663332Crohns Disease, Colitis, Ulcerative, Arthritis, Psoriatic, Arthritis, Juvenile
DrugGuselkumab
Janssen Research & Development, LLC
Phase 3
196
Georgia, Indiana, Ohio, Texas, Utah
2024-10-29
Recruiting
Safety Study of SMOFlipid to Evaluate the Risk of Developing EFAD and/or PNAC in Pediatric and Adult Patients
NCT06049680Malnutrition, Child, Malnutrition, Essential Fatty Acid Deficiency (EFAD), Parenteral Nutrition Associated Cholestasis
DrugSmoflipid
Fresenius Kabi
Phase 4
100
Georgia, Illinois, Indiana, Ohio, Pennsylvania
2024-10-28
Active, closed
Long-term Outcomes Among Patients With Programmed Death-ligand 1 <1% Metastatic Non-small Cell Lung Cancer Treated With First-line Nivolumab + Ipilimumab + 2 Cycles of Chemotherapy
NCT07024862Metastatic Non-small Cell Lung Cancer
DrugsIpilimumab·Nivolumab
Bristol-Myers Squibb
Observational
100
Ohio
2024-10-24
Active, closed
Study to Evaluate Avacopan in Combination With a Rituximab or Cyclophosphamide-containing Regimen, in Children From 6 Years to < 18 Years of Age With AAV.
NCT06321601Vasculitis
DrugAvacopan
Amgen
Phase 3
19
Georgia, Indiana, Minnesota, New York, North Carolina, Ohio, Pennsylvania, Texas
2024-10-22
Recruiting
FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations
NCT06669117Solid Tumor, MET Alteration
Pierre Fabre Medicament
Phase 1/2
140
District of Columbia, Ohio, Tennessee
2024-10-22
Active, closed
Long-term Extension Study of Ulviprubart (ABC008) in Subjects With Inclusion Body Myositis
NCT06450886Inclusion Body Myositis (IBM)
Abcuro, Inc.
Phase 2/3
270
Arizona, California, Connecticut, Massachusetts, New York, North Carolina, Ohio, Pennsylvania
2024-10-21
Recruiting
Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia
NCT06549790Relapsed/Refractory Acute Myeloid Leukemia
Nerviano Medical Sciences
Phase 1
124
California, Colorado, Delaware, Georgia, Minnesota, Ohio, Texas
2024-10-16
Active, closed
Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND)
NCT06553768Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)
DrugMaralixibat
Mirum Pharmaceuticals, Inc.
Phase 3
90
California, Illinois, New York, Ohio, Texas, Utah
2024-10-14
Recruiting
FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer
NCT06636682Prostate Cancer (Adenocarcinoma), Prostate CA, Prostate Cancers, Prostate Cancer (Post Prostatectomy)
Cellvax Therapeutics Inc
Phase 2
100
Illinois, Ohio, South Carolina
2024-10-14
Recruiting
Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis
NCT06619990Ulcerative Colitis (UC)
Xencor, Inc.
Phase 1/2
270
Arizona, California, Florida, Kentucky, Mississippi, New York, North Carolina, Ohio
2024-10-10
Active, closed
Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT)
NCT05417789TGCT
DrugEmactuzumab
SynOx Therapeutics Limited
Phase 3
128
California, Ohio, Texas, Washington
2024-10-09
Active, closed
A Clinical Trial to Assess the Agent Paclitaxel Coated PTCA Balloon Catheter for the Treatment of Subjects With In-Stent Restenosis (ISR) - Long Lesion Cohort
NCT06492174In-Stent Restenosis
Boston Scientific Corporation
Phase 3
20
Arizona, California, Georgia, Michigan, New York, Ohio, Pennsylvania, Rhode Island
2024-10-07
Recruiting
Study to Assess Real-world Effectiveness of Belimumab for Treatment of Adults With LN
NCT06527872Lupus Nephritis
GlaxoSmithKline
Observational
300
Maryland, North Carolina, Ohio, Tennessee
2024-10-04
Active, closed
A Study of RhinAer Stylus for Treating Chronic Rhinitis
NCT06599736Chronic Rhinitis
Aerin Medical
Not applicable
25
Colorado, Ohio
2024-10-03
Recruiting
Modulation of SERCA2a of Intra-Myocytic Calcium Trafficking in Cardiomyopathy Secondary to Duchenne Muscular Dystrophy
NCT06224660DMD-Associated Dilated Cardiomyopathy
Sardocor Corp.
Phase 1
12
Kansas, Ohio
2024-10-02
Recruiting
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
NCT06568692Breast Cancer, TNBC - Triple-Negative Breast Cancer, HER2-negative Breast Cancer
DrugCapecitabine
Processa Pharmaceuticals
Phase 2
90
Arizona, California, Florida, Indiana, Maryland, New Jersey, New York, Ohio
2024-10-02
Recruiting
Infant Formula in Infants and Children With Cow's Milk Allergy
NCT06456541Cow's Milk Allergy
Abbott Nutrition
Not applicable
96
Arizona, Colorado, Illinois, Michigan, North Carolina, Ohio, Texas
2024-10-01
Recruiting
APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML
NCT06634394Acute Myeloid Leukemia (AML)
DrugsVenclexta·Azacitidine·Venetoclax
Aptevo Therapeutics
Phase 1
39
Colorado, Florida, Kansas, Ohio, Texas
2024-10-01
Recruiting
Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia
NCT06584357Mild Cognitive Impairment, Alzheimer's Disease, Alzheimer's Disease, Early Onset, Memory Loss
GAP Innovations, PBC
Observational
1,200
Florida, Illinois, Michigan, Nevada, New York, Ohio, Pennsylvania, Rhode Island
2024-09-26
Recruiting
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
NCT06463665Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Squamous Non-Small Cell Lung Carcinoma
DrugsOlvi-Vec·Olvimulogene nanivacirepvec·Docetaxel·Cisplatin
Genelux Corporation
Phase 2
142
Arizona, Florida, Michigan, New Jersey, Ohio, Texas
2024-09-26
Recruiting
Evaluate the Safety and Effectiveness of the AccuraSee™ IOPCL for Secondary Implantation in the Capsular Bag to Improve Near and/or Intermediate Vision Following Previous Cataract Surgery
NCT06625749Refractive Surgery, Refractive Error - Myopia
OnPoint Vision Inc
Not applicable
10
Ohio
2024-09-23
Recruiting
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
NCT06561685Metastatic Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer, SMARCA4-Deficient Tumor
DrugsNab-paclitaxel·Pemetrexed·Paclitaxel·Cisplatin
Eli Lilly and Company
Phase 1
340
California, Colorado, Florida, Illinois, Massachusetts, New York, Ohio, Tennessee
2024-09-19
Active, closed
Safety and Effectiveness of Cochlear Implantation in an Expanded Adult Population
NCT06293482Hearing Loss, Sensorineural, Hearing Loss, Bilateral
Cochlear
Not applicable
50
Arizona, California, Florida, Indiana, Missouri, New York, Ohio, Pennsylvania
2024-09-17
Active, closed
A Clinical Study to Evaluate DNTH103 in Adults With Multifocal Motor Neuropathy
NCT06537999Multifocal Motor Neuropathy
DrugClaseprubart
Dianthus Therapeutics
Phase 2
46
Arizona, California, Florida, Hawaii, Kansas, Ohio, Texas
2024-09-17
Recruiting
The TRICURE EFS Study
NCT06506942Tricuspid Valve Regurgitation, Heart Valve Diseases, Cardiovascular Diseases
TRiCares
Not applicable
15
Georgia, Illinois, Michigan, Minnesota, New York, Ohio, South Carolina
2024-09-11
Active, closed
ABA-101 in Participants With Progressive Multiple Sclerosis
NCT06566261Progressive Multiple Sclerosis
Abata Therapeutics
Phase 1
12
Maryland, New Jersey, Ohio
2024-09-11
Recruiting
A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B
NCT06379789Hemophilia B
Regeneron Pharmaceuticals
Phase 1/2
130
California, Colorado, Connecticut, Florida, Indiana, Louisiana, Michigan, Ohio
2024-09-11
Active, closed
A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
NCT06311721Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
DrugsABP 234·Keytruda·Pembrolizumab
Amgen
Phase 3
315
California, Florida, Illinois, Iowa, Michigan, New York, Ohio, Texas
2024-09-09
Recruiting
RevCore for In Stent Thrombosis
NCT06394739In-stent Thrombosis
Inari Medical
Observational
100
Connecticut, District of Columbia, Idaho, Maryland, New York, North Carolina, Ohio, Pennsylvania
2024-09-09
Recruiting
A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.
NCT06476808High-grade Serous Ovarian Carcinoma (HGSOC), Uterine Serous Carcinoma (USC), Non-small Cell Lung Cancer (NSCLC)
Bristol-Myers Squibb
Phase 1
240
California, New Jersey, Ohio, Texas
2024-09-06
Recruiting
A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
NCT06393738Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL), Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)
DrugGlofitamab
Arvinas Inc.
Phase 1
329
Connecticut, Florida, Michigan, New Jersey, New York, Ohio, Tennessee, Texas
2024-09-05
Active, closed
The SpeedPlate™ Rapid Compression Implant Study (The SPRINT™ Study)
NCT06548581Joint Arthrodesis, Joint Fixation
Treace Medical Concepts, Inc.
Observational
92
Alabama, Florida, Missouri, Ohio, Texas
2024-09-04
Recruiting
A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD Participants
NCT06576271Systemic Lupus Erythematosus
DrugBelimumab
GlaxoSmithKline
Phase 1
142
Arizona, Colorado, Nevada, Ohio, Oklahoma, Texas
2024-09-02
Recruiting
Safety, PK, PD, Dosing, and Efficacy of RLS-0071for the Treatment of Hospitalized Patients With Steroid-Refractory Acute Graft-versus-Host Disease
NCT06343792Steroid Refractory GVHD
DrugRLS-0071
ReAlta Life Sciences, Inc.
Phase 2
66
California, Georgia, Missouri, Ohio
2024-08-31
Recruiting
Study With [225Ac]Ac-FL-020 in mCRPC Participants
NCT06492122Metastatic Castration-resistant Prostate Cancer
DrugBlood samples for PK
Full-Life Technologies UK Limited
Phase 1
50
California, Ohio, Virginia
2024-08-30
Active, closed
A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR)
NCT06503731Antibody-mediated Rejection
argenx
Phase 2
33
Alabama, California, Illinois, Nebraska, North Carolina, Ohio, Virginia, Washington
2024-08-30
Recruiting
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
NCT06500884Multiple Myeloma
DrugsRamantamig·Talquetamab
Janssen Research & Development, LLC
Phase 2
210
California, Colorado, Connecticut, New York, North Carolina, Ohio, Virginia, Washington
2024-08-26
Recruiting
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
NCT06535607Sub-study 1 Cervical Cancer (Volrustomig Monotherapy), Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy), Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy), Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)
DrugsVolrustomig·Adrucil·Paclitaxel·Cisplatin
AstraZeneca
Phase 2
257
California, Maryland, New York, Ohio, Pennsylvania
2024-08-22
Recruiting
Abbott Structural Heart Device Registry
NCT06590467Heart Diseases, ASD - Atrial Septal Defect, VSD - Muscular Ventricular Septal Defect, PFO - Patent Foramen Ovale
Abbott Medical Devices
Observational
2,500
California, District of Columbia, Florida, Missouri, New Jersey, New York, Ohio, Pennsylvania
2024-08-21
Recruiting
Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-Resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass
NCT06096116Acquired Antithrombin Deficiency
Octapharma
Phase 3
120
California, Florida, Massachusetts, North Carolina, Ohio, Oklahoma, Texas
2024-08-21
Active, closed
A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis
NCT06284954Dermatomyositis, Myositis
DrugEmpasiprubart
argenx
Phase 2
3
California, Florida, Ohio
2024-08-20
Recruiting
A Study to Evaluate the Efficacy of a Purified Native Type 1 Collagen Extracellular Matrix With Polyhexamethylene Biguanide Antimicrobial (PCMP) and Standard of Care Versus Standard of Care Alone in the Management of Nonhealing Diabetic Foot Ulcers
NCT06618612Diabetic Foot Ulcer
Organogenesis
Not applicable
170
Ohio
2024-08-19
Recruiting
Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
NCT06371417Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP), Behçet's Syndrome (BS), Dermatomyositis (DM)
DrugRAY121
Chugai Pharmaceutical
Phase 1
144
California, Maryland, New York, North Carolina, Ohio, Oregon, Pennsylvania, Texas
2024-08-19
Recruiting
Nafamostat Efficacy in Phase 3 Registrational CRRT Study
NCT06150742Acute Kidney Injury
Talphera, Inc
Not applicable
70
California, Florida, Michigan, New Mexico, New York, Ohio, Pennsylvania, South Carolina
2024-08-15
Active, closed
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
NCT06577987Advanced Solid Tumor, Metastatic Solid Tumor, Refractory Solid Tumor, Cancer
Circle Pharma
Phase 1
220
Florida, Massachusetts, Michigan, Nevada, Ohio, Oregon, Tennessee, Texas
2024-08-14
Recruiting
SMP-3124LP in Adults With Advanced Solid Tumors
NCT06526819Solid Tumor
Sumitomo Pharma America, Inc.
Phase 1/2
120
California, Colorado, Florida, Illinois, Ohio, Tennessee, Texas, Washington
2024-08-14
Recruiting
Melodi Matrix™ in Breast Reconstruction
NCT06027996Breast Reconstruction
Melodi Health, Inc.
Not applicable
702
California, Michigan, Minnesota, New York, Ohio, Pennsylvania, South Carolina, South Dakota
2024-08-09
By invitation
Kerecis Real-World Fish Skin Graft Registry
NCT06384183Wounds, Pressure Ulcer, Diabetic Foot Ulcer, Venous Leg Ulcer
Kerecis Ltd.
Observational
600
Florida, North Carolina, Ohio, Texas
2024-08-07
Active, closed
Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)
NCT06162572Non-small Cell Lung Cancer (NSCLC)
DrugsS095029·Cemiplimab
Servier Bio-Innovation LLC
Phase 1/2
102
Michigan, Ohio
2024-08-07
Recruiting
A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
NCT06292780Relapsed/Refractory Systemic Light Chain Amyloidosis
DrugLinvoseltamab
Regeneron Pharmaceuticals
Phase 1/2
220
California, Colorado, Massachusetts, Michigan, New York, Ohio, Tennessee, Texas
2024-08-07
Recruiting
Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC)
NCT06549465PSMA PET-Positive Castration-Resistant Prostate Cancer
Convergent Therapeutics
Phase 2
93
California, Massachusetts, Missouri, Nebraska, New York, North Carolina, Ohio
2024-08-06
Recruiting
Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder
NCT06480383Generalized Anxiety Disorder
DrugITI-1284
Intra-Cellular Therapies, Inc.
Phase 2
705
California, Florida, Georgia, Michigan, New Jersey, New York, Ohio, Oklahoma
2024-08-05
Recruiting
Innoventric Trillium™ Stent Graft Early Feasibility Study (EFS)
NCT06212193Tricuspid Regurgitation, Tricuspid Regurgitation Functional
Innoventric LTD
Not applicable
15
California, Michigan, Minnesota, New York, Ohio, Pennsylvania, Tennessee, Washington
2024-08-05
Recruiting
Modified Multi-Platform Trial Assessing Multiple CAMPs and SOC vs SOC Alone in the Treatment of DFU and VLUs
NCT06560502Diabetic Foot Ulcer, Venous Leg Ulcer, Ulcer Foot, Leg Ulcer
Stability Biologics
Not applicable
324
Ohio
2024-08-01
Recruiting
CardiAMP Heart Failure II Trial for Patients With Ischemic Heart Failure With Reduced Ejection Fraction
NCT06258447Ischemic Heart Failure
BioCardia, Inc.
Not applicable
250
Florida, Georgia, Michigan, Ohio, Wisconsin
2024-08-01
Recruiting
SW-682 in Advanced Solid Tumors
NCT06251310Advanced Solid Tumor, Mesothelioma, Malignant
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Phase 1
186
Arizona, California, Ohio, Oregon, Texas
2024-07-31
Recruiting
Study of BB-031 in Acute Ischemic Stroke Patients (RAISE)
NCT06226805Acute Ischemic Stroke
Basking Biosciences, Inc.
Phase 2
228
Arizona, California, Florida, Michigan, Missouri, New Jersey, North Carolina, Ohio
2024-07-31
Active, closed
A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
NCT06147037Advanced Solid Tumor, Metastatic Colorectal Carcinoma, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer
AstraZeneca
Phase 1
13
California, Illinois, Nebraska, Ohio, Texas, Washington
2024-07-31
Active, closed
Visual Performance of Center Distance Daily Disposable Multifocal Lenses
NCT06475053Myopia
Visioneering Technologies, Inc
Not applicable
30
Ohio
2024-07-31
Active, closed
SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations
NCT06239480Microcystic Lymphatic Malformation
DrugQTORIN rapamycin anhydrous
Palvella Therapeutics, Inc.
Phase 3
51
California, Georgia, Minnesota, New York, North Carolina, Ohio, Pennsylvania, Tennessee
2024-07-31
Recruiting
The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)
NCT06520345Metastatic Castration-resistant Prostate Cancer
DrugsAbiraterone·Enzalutamide·Docetaxel
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 3
520
California, Florida, Maryland, Nebraska, New York, Ohio, Oregon, Utah
2024-07-26
Active, closed
Phase 2 Open-label Extension Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)
NCT06547216FSHD, FSHD1, FSHD2, FMD
DrugDel-brax
Avidity Biosciences, Inc.
Phase 2
84
California, Colorado, Florida, Georgia, Kansas, New York, North Carolina, Ohio
2024-07-25
Recruiting
JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation
NCT06386146Solid Tumors
Jacobio Pharmaceuticals Co., Ltd.
Phase 1/2
144
Colorado, Florida, Missouri, Ohio, Tennessee, Texas
2024-07-24
Recruiting
An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
NCT06480552Advanced Solid Tumors
DrugsTEV-56278·Keytruda·Pembrolizumab
Teva Branded Pharmaceutical Products R&D LLC
Phase 1
240
California, Florida, Illinois, Michigan, North Carolina, Ohio, Pennsylvania, Tennessee
2024-07-22
Recruiting
QUELIMMUNE (SCD-PED) PediAtric SurVeillance REgistry
NCT06517810Acute Kidney Injury, Acute Kidney Injury Due to Sepsis
SeaStar Medical
Observational
50
Alabama, California, Colorado, Georgia, Illinois, Michigan, Ohio, Pennsylvania
2024-07-19
Active, closed
A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)
NCT06483334Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma
DrugsEnfortumab Vedotin·Sacituzumab tirumotecan·Keytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 1/2
38
California, Illinois, Indiana, Massachusetts, Missouri, New York, Ohio, Utah
2024-07-17
Recruiting
Safety Evaluation of Prismocitrate 18 in Patients Receiving CRRT
NCT05399537Regional Citrate Anticoagulation (RCA), Continuous Renal Replacement Therapy (CRRT), Acute Kidney Injury (AKI)
Vantive Health LLC
Phase 3
40
Alabama, California, Florida, Georgia, Michigan, Ohio, Pennsylvania, South Carolina
2024-07-12
Recruiting
Zopa Retreatment and Vector Shedding in Adults With RRP
NCT06538480Recurrent Respiratory Papillomatosis, Papillomavirus Infection, Papillomaviridae
Precigen, Inc
Phase 4
30
Georgia, Maryland, Ohio
2024-07-11
Recruiting
A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
NCT06100744Juvenile Psoriatic Arthritis
DrugsSkyrizi·Risankizumab·Adalimumab
AbbVie
Phase 3
40
Arkansas, District of Columbia, Florida, Indiana, Minnesota, New York, North Carolina, Ohio
2024-07-08
Active, closed
Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune Disease
NCT06293365Sjögrens Disease, Systemic Lupus Erythematosus, Rheumatoid Arthritis
DrugIanalumab
Novartis Pharmaceuticals
Phase 2
155
Alabama, California, Florida, Georgia, Indiana, Louisiana, Michigan, Ohio
2024-07-02
Active, closed
Transorb™ Self-Gripping Resorbable Mesh in High-risk Subjects Undergoing Open Repair of Ventral Hernia
NCT06449378Hernia, Hernia, Ventral, Hernia, Abdominal, Hernia Abdominal Wall
Medtronic - MITG
Not applicable
163
Illinois, Kentucky, North Carolina, Ohio, Virginia
2024-07-02
Recruiting
Retrospective-Prospective PNS Study
NCT06845631Chronic Pain
Curonix LLC
Not applicable
40
Ohio
2024-07-01
Recruiting
A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)
NCT06263231Sarcoma,Soft Tissue
DrugsINT230-6·Trabectedin·Pazopanib·Eribulin
Intensity Therapeutics, Inc.
Phase 3
333
California, Connecticut, Michigan, Nebraska, North Carolina, Ohio, Pennsylvania
2024-06-28
Active, closed
Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)
NCT06331312Polymyalgia Rheumatica
DrugSecukinumab
Novartis Pharmaceuticals
Phase 3
162
Arizona, California, Florida, Maryland, Michigan, New Hampshire, Ohio, Texas
2024-06-28
Recruiting
HPC Offered for PRESERVE Expansion
NCT07145411Bone Marrow Transplant (BMT)
Ossium Health, Inc.
Observational
10
Alabama, Michigan, Ohio, Tennessee
2024-06-27
Active, closed
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
NCT06447662Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
Pfizer
Phase 1
64
Arkansas, California, Colorado, District of Columbia, Michigan, Missouri, North Carolina, Ohio
2024-06-27
Recruiting
BiVACOR® Total Artificial Heart Early Feasibility Study
NCT06174103Heart Failure, Biventricular Failure
BiVACOR Inc.
Not applicable
20
Arizona, North Carolina, Ohio, Texas
2024-06-26
Recruiting
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
NCT06463587Generalized Myasthenia Gravis
DrugCladribine
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 3
264
Arizona, Colorado, Connecticut, District of Columbia, Florida, Kansas, North Carolina, Ohio
2024-06-25
Recruiting
A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of BC3195 in Patients With Advanced or Metastatic Cancer
NCT06548672Advanced Cancer, Metastatic Solid Tumor
DrugBC3195
Biocity Biopharmaceutics Co., Ltd.
Phase 1
148
Ohio
2024-06-24
Recruiting
KiteLock 4% EDTA Lock Solution for the Prevention of Occlusions in Children With Intestinal Failure
NCT05879835Pediatric Intestinal Failure
SterileCare Inc.
Not applicable
124
Massachusetts, Nebraska, New York, North Carolina, Ohio, Texas, Washington
2024-06-21
Recruiting
Prescreening Study to Identify Potential Stargardt Participants for ACDN-01 Clinical Trials (STARPATH)
NCT06445322Stargardt Disease, Stargardt Disease 1, Cone Rod Dystrophy, Juvenile Macular Degeneration
Ascidian Therapeutics, Inc
Observational
50
California, Florida, Maryland, Massachusetts, Michigan, Ohio, Texas
2024-06-20
Recruiting
Evaluation of the Patellar LIFT System for Subjects With Patellofemoral Cartilage Degeneration
NCT06423300Patellofemoral Osteoarthritis
ZKR Orthopedics Inc
Not applicable
245
California, New York, Ohio, Oregon
2024-06-19
Recruiting
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
NCT06501196Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Preleukemia
DrugsVenclyxto·Venclexta·Venetoclax
BlossomHill Therapeutics
Phase 1
170
California, Florida, Illinois, New York, Ohio, Tennessee, Texas, Washington
2024-06-19
Recruiting
Study of SGR-3515 In Participants With Advanced Solid Tumors.
NCT06463340Advanced Solid Tumor
Schrödinger, Inc.
Phase 1
52
Connecticut, Illinois, Michigan, New York, North Carolina, Ohio, Oklahoma, Tennessee
2024-06-18
Recruiting
Study of APR-1051 in Patients With Advanced Solid Tumors
NCT06260514Advanced Solid Tumor
Aprea Therapeutics
Phase 1
90
Ohio, Texas, Virginia
2024-06-13
Recruiting
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
NCT06303505Ovarian Cancer, Non-small Cell Lung Cancer
DrugTUB-040
Gilead Sciences
Phase 1/2
250
Alabama, Connecticut, Georgia, Kentucky, Massachusetts, New Jersey, New York, Ohio
2024-06-12
Recruiting
Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)
NCT06467344Stargardt Disease, Cone Rod Dystrophy, Juvenile Macular Degeneration, Stargardt Disease 1
Ascidian Therapeutics, Inc
Phase 1/2
15
California, Florida, Maryland, Massachusetts, Michigan, Ohio, Oregon, Texas
2024-06-11
Recruiting
Transdermal Compress IDE Study
NCT06134167Prosthesis and Implants
Balmoral Medical company
Not applicable
100
California, Colorado, Illinois, Maryland, New York, Ohio, Pennsylvania
2024-06-11
Recruiting
VasoStar Vibrational Guidewire System to Facilitate Crossing Coronary Artery Chronic Total Occlusions
NCT06193954Chronic Total Occlusion of Coronary Artery, Chronic Angina
VasoStar, LLC
Not applicable
10
Georgia, Ohio
2024-06-10
Recruiting
MagnetOs Flex Matrix Compared to Trinity Elite Mixed With Local Autograft in Patients Undergoing up to Four-level Instrumented Posterolateral Fusion
NCT05037968Degenerative Disc Disease, Spine Fusion, Leg Pain and/or Back Pain
Kuros Biosurgery AG
Not applicable
100
Connecticut, Illinois, Maryland, Michigan, North Carolina, Ohio, Utah, Virginia
2024-06-10
Active, closed
A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT06425991Multiple Myeloma
DrugTeclistamab
Janssen Research & Development, LLC
Phase 1
108
Arizona, Colorado, Florida, Georgia, Indiana, Ohio, Texas
2024-06-07
Active, closed
NOX1416 in Treatment of Chronic Non-Healing Diabetic Foot Ulcers
NCT06402565Diabetic Foot Ulcer
NOxy Health Products, LLC
Phase 1
40
Arizona, Florida, Massachusetts, Ohio, Texas
2024-06-06
Recruiting
Prospective Clinical Assessment Study in Children With Hypochondroplasia
NCT06410976Hypochondroplasia
QED Therapeutics, a BridgeBio company
Observational
150
California, Colorado, District of Columbia, Maryland, Missouri, Ohio, Tennessee, Wisconsin
2024-06-05
Recruiting
Safety, PK/PD, and Exploratory Efficacy Study of AMT-191 in Classic Fabry Disease
NCT06270316Fabry Disease
UniQure Biopharma B.V.
Phase 1/2
20
Alabama, California, Georgia, Illinois, Minnesota, New York, Ohio, Pennsylvania
2024-06-05
Active, closed
A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
NCT06507306Solid Tumor, Adult
DrugsKQB198·Tagrisso·Amivantamab·Osimertinib
Kumquat Biosciences Inc.
Phase 1
92
Colorado, Florida, Michigan, New York, Ohio, Tennessee, Texas, Virginia
2024-06-03
Recruiting
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
NCT06343311B-Cell Non-Hodgkin's Lymphoma (NHL), Lymphoma, Non-Hodgkins, Lymphomas Non-Hodgkin's B-Cell, Non-Hodgkin Lymphoma
Estrella Immunopharma, Inc.
Phase 1/2
27
California, Ohio, Oregon, Texas, Utah
2024-06-01
Recruiting
Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)
NCT05804370Ovarian Cancer
DrugGleolan
NX Development Corp
Phase 3
170
Arizona, Florida, Maryland, Minnesota, New York, Ohio, Pennsylvania, Virginia
2024-05-30
Recruiting
Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated or Spliceosome Mutated Relapsed or Refractory Acute Myeloid Leukemia
NCT06366789AML With Gene Mutations
Lomond Therapeutics Holdings, Inc.
Phase 1
150
California, Georgia, Illinois, Kansas, Maryland, New York, North Carolina, Ohio
2024-05-29
Recruiting
A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
NCT06351631Thrombocythemia, Essential, Primary Myelofibrosis, Myelofibrosis, Post-polycythemia Vera Myelofibrosis
DrugBomedemstat
Merck Sharp & Dohme LLC
Phase 3
400
Michigan, North Carolina, Ohio, Pennsylvania
2024-05-23
Recruiting
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
NCT06353386Prostatic Neoplasms, Castration-Resistant
DrugsFludrocortisone acetate·Opevesostat·Cabazitaxel·Taxotere
Merck Sharp & Dohme LLC
Phase 1/2
220
California, Florida, Maryland, New Jersey, Ohio, Wisconsin
2024-05-20
Recruiting
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
NCT06400472Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Non-Small-Cell Lung
DrugsSofe-M·Itraconazole·Bevacizumab·Carboplatin
Eli Lilly and Company
Phase 1
575
Arizona, California, Georgia, Michigan, New York, Ohio, Texas, Utah
2024-05-20
Recruiting
Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis
NCT06414954Myasthenia Gravis, Myasthenia Gravis, MuSK
NMD Pharma A/S
Phase 2
84
California, Colorado, Florida, Georgia, Missouri, North Carolina, Ohio, Oregon
2024-05-16
Active, closed
Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma
NCT05739942Newly Diagnosed and Recurrent Glioblastoma
DrugsGa-NeoB·Lu-NeoB
Novartis Pharmaceuticals
Phase 1
42
California, Colorado, Massachusetts, New York, Ohio, Utah
2024-05-15
Recruiting
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
NCT06395519Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Prostate Cancer
858 Therapeutics, Inc.
Phase 1/2
120
Arizona, Connecticut, Florida, Illinois, Massachusetts, Minnesota, New York, Ohio
2024-05-13
Recruiting
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
NCT06425926Melanoma Stage IV, Solid Tumor
Georgiamune Inc
Phase 1/2
117
Arizona, California, Massachusetts, Montana, New York, Ohio, Tennessee, Virginia
2024-05-09
Recruiting
Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients
NCT05703971Small Cell Lung Cancer Extensive Stage
DrugsQuaratusugene ozeplasmid·Tecentriq·Atezolizumab
Genprex, Inc.
Phase 1/2
62
Colorado, Missouri, Ohio, Oregon, Texas, Virginia, Washington
2024-05-09
Recruiting
A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE)
NCT06138639Duchenne Muscular Dystrophy
Solid Biosciences Inc.
Phase 1/2
60
Arkansas, California, Georgia, Illinois, Missouri, Ohio, Oregon, Pennsylvania
2024-05-06
Recruiting
Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
NCT06249048Advanced Solid Tumor
DrugsKeytruda·Pembrolizumab
Strand Therapeutics Inc.
Phase 1/2
108
Arizona, California, Ohio, Pennsylvania, Texas, Utah
2024-05-03
Recruiting
Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors
NCT06384352Advanced Solid Tumors
DrugsPemetrexed·Cisplatin·Carboplatin·Pembrolizumab
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1
500
Colorado, Connecticut, Florida, Nevada, Ohio, Texas
2024-05-01
Recruiting
Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema Attacks
NCT06361537Acute Hereditary Angio Edema
Octapharma
Phase 3
124
Colorado, Michigan, Ohio
2024-04-30
Active, closed
S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP
NCT06188702MTAP-deleted Solid Tumors
DrugTNG462
Servier Bio-Innovation LLC
Phase 1/2
60
Florida, Indiana, Ohio, Tennessee, Texas
2024-04-29
Recruiting
A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product
NCT05768269Hematological Malignancy, Solid Tumor Malignancy
Century Therapeutics, Inc.
Observational
375
Arizona, California, Maryland, Michigan, North Carolina, Ohio, Washington
2024-04-29
Recruiting
A Clinical Study of the TSX Dental Implant System (Xpresso)
NCT06571812Tooth Loss
ZimVie
Observational
62
Ohio, Pennsylvania
2024-04-24
Recruiting
A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
NCT05980806Myelofibrosis, Moderate Thrombocytopenia, Mild Thrombocytopenia
DrugsMomelotinib·Pacritinib·Selinexor·Ruxolitinib
Karyopharm Therapeutics Inc
Phase 2
58
California, Maryland, New York, North Carolina, Ohio, Texas, Utah
2024-04-22
Recruiting
A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs
NCT06228326Lung Cancer, Non-small Cell, Lung Cancer Metastatic, Solid Tumor, Adult, Advanced Cancer
DrugsKB707·Docetaxel·Keytruda·Pembrolizumab
Krystal Biotech, Inc.
Phase 1/2
250
Alabama, Arizona, California, Florida, Indiana, Louisiana, Michigan, Ohio
2024-04-17
Recruiting
A Real-world Long-term Safety and Immunogenicity Study of Olipudase Alfa Therapy in Pediatric Patients Less Than 2 Years of Age With Acid Sphingomyelinase Deficiency (ASMD)
NCT06192576Niemann-Pick Diseases, Acid Sphingomyelinase Deficiency
Sanofi
Observational
10
Illinois, Ohio, Pennsylvania, Texas, Utah
2024-04-16
Active, closed
A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis
NCT06298552Generalized Myasthenia Gravis, gMG, Myasthenia Gravis, Generalized, Myasthenia Gravis
DrugEfgartigimod
argenx
Phase 3
119
Arizona, California, Florida, Georgia, Kansas, New Jersey, North Carolina, Ohio
2024-04-16
Active, closed
P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies
NCT06014762Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High-grade B-cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL), Transformed Follicular Lymphoma (tFL)
DrugRimiducid
Poseida Therapeutics, Inc.
Phase 1
120
California, Florida, Indiana, Louisiana, Michigan, New York, North Carolina, Ohio
2024-04-16
Recruiting
Aptis PRUJ Prosthesis for the Treatment of Patients With Proximal Radial Ulna Joint Disorders.
NCT05796908Arthritis, Unstable Radial Head, Proximal Radioulnar Joint Instability, Decreased Motion at the Proximal Radioulnar Joint and/or the Radio-humeral Joint
Aptis Medical
Not applicable
84
Indiana, Kentucky, Massachusetts, Ohio, Pennsylvania, Wisconsin
2024-04-12
Recruiting
Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors
NCT06233942Advanced Solid Tumor
DrugsTislelizumab·Bevacizumab
BeOne Medicines
Phase 1
308
California, Colorado, Florida, Maryland, Ohio
2024-04-12
Active, closed
Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease
NCT06125951Dementia Moderate, Dementia, Mild, Alzheimer Disease
Actinogen Medical
Phase 2/3
247
California, Colorado, Florida, Georgia, New Jersey, New York, Ohio, Oregon
2024-04-12
Active, closed
Medtronic Hugo™ Robotic Assisted Surgery (RAS) System in Hernia Surgery (Enable Hernia Repair)
NCT06445504Inguinal Hernia, Ventral Hernia
Medtronic - MITG
Not applicable
206
Florida, Illinois, New York, North Carolina, Ohio, Texas, Virginia
2024-04-08
Active, closed
An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)
NCT06073132Generalized Epidermolysis Bullosa Simplex
TWi Biotechnology, Inc.
Phase 2/3
80
California, Colorado, Illinois, Ohio, South Carolina, Texas
2024-04-04
Recruiting
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
NCT05932862Advanced Solid Tumor
DrugOlaparib
Exelixis
Phase 1
429
California, Florida, Minnesota, Missouri, New Jersey, New York, Ohio, Oklahoma
2024-04-03
Recruiting
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
NCT06051695Solid Tumor, Adult, Colorectal Cancer, NSCLC, Non Small Cell Lung Cancer
A2 Biotherapeutics Inc.
Phase 1/2
474
Arizona, California, Florida, Minnesota, Missouri, New York, Ohio, Tennessee
2024-04-03
Recruiting
Clinical Safety and Efficacy of the VDyne Transcatheter Tricuspid Valve Replacement System for the Treatment of Tricuspid Regurgitation ( VISTA-US)
NCT05848284Tricuspid Regurgitation, Tricuspid Valve Disease, Tricuspid Valvular Disorders
VDyne, Inc.
Not applicable
30
California, Michigan, Minnesota, New York, Ohio, Oregon, South Carolina, Tennessee
2024-04-01
Recruiting
A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
NCT06308978Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM), Systemic Sclerosis (SSc), Systemic Lupus Erythematosus (SLE)
DrugsFT819·Fludara·Bendamustine·Cytoxan
Fate Therapeutics
Phase 1
244
California, Florida, Kentucky, Minnesota, Nebraska, New York, North Carolina, Ohio
2024-03-28
Active, closed
A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)
NCT06305767Bladder Cancer
DrugsIntismeran autogene·Enfortumab Vedotin·Keytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 1/2
230
California, Florida, Illinois, Iowa, New York, North Carolina, Ohio, Pennsylvania
2024-03-28
Recruiting
Open-label, Dose Escalation Study of Safety and Preliminary Efficacy of TN-401 in Adults With PKP2 Mutation-associated ARVC
NCT06228924Arrhythmogenic Right Ventricular Cardiomyopathy
Tenaya Therapeutics
Phase 1
15
California, Colorado, Maryland, Massachusetts, Minnesota, New York, Ohio
2024-03-26
Recruiting
Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera
NCT06093672Polycythemia Vera
DrugHydroxyurea
Italfarmaco
Phase 3
220
Alabama, California, Colorado, Maryland, New York, North Carolina, Ohio, Oregon
2024-03-26
By invitation
A Study of Precice Intramedullary Limb Lengthening System (IMLL) Limb Lengthening Procedures
NCT06741514Limb Length Discrepancy
NuVasive
Observational
100
Florida, Ohio
2024-03-25
Active, closed
Phase 2 Study of EDG-5506 in Children and Adolescents With Duchenne Muscular Dystrophy Previously Treated With Gene Therapy
NCT06100887Duchenne Muscular Dystrophy
DrugsSevasemten 1·Sevasemten 2·Sevasemten 3
Edgewise Therapeutics, Inc.
Phase 2
43
California, Florida, Massachusetts, Missouri, North Carolina, Ohio
2024-03-22
Recruiting
Efficacy and Safety Study of OATD-01 in Patients With Active Pulmonary Sarcoidosis
NCT06205121Pulmonary Sarcoidosis
Molecure S.A.
Phase 2
96
Alabama, Kansas, Maryland, Minnesota, Ohio, Pennsylvania, South Carolina
2024-03-21
Recruiting
Clinical and Healthcare Outcomes From Real-World Use in the United States of a Companion AI During AF Ablation
NCT06056271Atrial Fibrillation
Volta Medical
Observational
400
Illinois, Kansas, New York, Ohio
2024-03-19
Recruiting
LMY-920 for Treatment of Relapsed or Refractory Myeloma
NCT05546723Multiple Myeloma, Refractory, Multiple Myeloma in Relapse
Luminary Therapeutics
Phase 1
30
Ohio
2024-03-13
Recruiting
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
NCT05923073Crohn's Disease
DrugsTremfya·Guselkumab
Janssen Research & Development, LLC
Phase 3
120
California, Connecticut, Georgia, Indiana, Massachusetts, New Jersey, New York, Ohio
2024-03-13
Recruiting
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
NCT05509777Crohn's Disease
DrugMirikizumab
Eli Lilly and Company
Phase 3
90
California, Connecticut, Georgia, Indiana, Massachusetts, New Jersey, New York, Ohio
2024-03-13
Recruiting
Development of a Therapeutic Device to Improve Speech Sound Differentiation in Preterm Infants
NCT06063122Premature Birth
Thrive Neuromedical, LLC
Not applicable
203
Georgia, Ohio
2024-03-08
Recruiting
A Study to Evaluate the Utilization of 3D Printed Models in Pre-Operative Planning
NCT06387485Sarcoma, Ewing, Chondrosarcoma, Osteosarcoma, Fibrous Histiocytoma
Ricoh USA, Inc.
Not applicable
150
California, Michigan, Ohio
2024-03-01
Active, closed
An Open-label Extension Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis
NCT06169397Pulmonary Sarcoidosis
Xentria, Inc.
Phase 2
31
Colorado, Illinois, North Carolina, Ohio, Pennsylvania
2024-03-01
Active, closed
CLIP-IT Post-Market Study
NCT06203054Left Atrial Appendage Exclusion
Medtronic Cardiac Surgery
Not applicable
198
Georgia, Illinois, Indiana, Michigan, Minnesota, Missouri, New York, Ohio
2024-02-26
Active, closed
NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)
NCT05996003Duchenne Muscular Dystrophy, Exon 44, DMD
DrugBrogidirsen
NS Pharma, Inc.
Phase 2
20
Colorado, Georgia, Illinois, Kansas, Massachusetts, New York, Ohio, Pennsylvania
2024-02-22
Active, closed
A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors
NCT06244485Advanced Solid Tumor
DrugsValemetostat Tosylate·Dato-DXd·Trastuzumab deruxtecan
Daiichi Sankyo
Phase 1
210
California, Florida, Hawaii, Illinois, Massachusetts, New York, North Carolina, Ohio
2024-02-22
Active, closed
SkinTE® for the Treatment of Wagner 1 Diabetic Foot Ulcers (COVER DFUS II)
NCT06140303Diabetic Foot
PolarityTE
Phase 3
100
Arizona, California, Florida, Maryland, Nevada, New York, Ohio, Texas
2024-02-22
Recruiting
Early Feasibility Study (EFS) Laplace Transcatheter Tricuspid Valve Replacement (TTVR) System
NCT06183684Tricuspid Regurgitation
Laplace Interventional, Inc
Not applicable
65
Arizona, California, Georgia, Minnesota, New Hampshire, New York, Ohio, Oklahoma
2024-02-19
Active, closed
ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function
NCT05907096Delayed Graft Function
DrugEmpasiprubart
argenx
Phase 2
103
California, Florida, Illinois, New Jersey, New York, Ohio, Texas
2024-02-17
Recruiting
Oral Pyridoxal 5'-Phosphate for the Treatment of Patients With PNPO Deficiency
NCT04706013Pyridox(am)Ine 5'-Phosphate Oxidase Deficiency
Medicure
Phase 3
15
Alabama, California, Colorado, Massachusetts, North Carolina, Ohio
2024-02-16
Recruiting
A Natural History Study in Participants With Congenital Myasthenic Syndromes (CMS) Due to Mutations in DOK7, MUSK, AGRN, or LRP4
NCT06078553Congenital Myasthenic Syndrome
argenx
Observational
100
California, Illinois, Massachusetts, Minnesota, Ohio, Pennsylvania
2024-02-13
Active, closed
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
NCT06151574Lung Cancer, Non-squamous, Non-small Cell
DrugsZongertinib·Pemetrexed·Keytruda·Cisplatin
Boehringer Ingelheim
Phase 3
428
Alabama, Arizona, California, Missouri, Nevada, New York, North Carolina, Ohio
2024-02-09
Recruiting
Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors
NCT05868629Rare Unresectable or Metastatic BRAF V600E Mutation-positive Solid Tumors
Novartis Pharmaceuticals
Observational
40
California, Colorado, District of Columbia, North Carolina, Ohio, Tennessee, Texas
2024-02-06
Active, closed
A Study About Antibody Levels and Biomarkers in the Blood in People With Late-onset Pompe Disease
NCT06150820Pompe Disease (Late-onset)
Astellas Gene Therapies
Not applicable
119
Georgia, Kansas, Michigan, Minnesota, New Jersey, Ohio, Pennsylvania, Utah
2024-02-01
Recruiting
Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies
NCT05966467Neuromyelitis Optica Spectrum Disorder, NMOSD, AQP4+ NMOSD
Alexion Pharmaceuticals, Inc.
Observational
122
District of Columbia, Massachusetts, North Carolina, Ohio, Texas, Wisconsin
2024-02-01
Recruiting
An Open-Label Study of CTI-1601 in Subjects With Friedreich's Ataxia
NCT06447025Friedreich Ataxia
DrugNomlabofusp
Larimar Therapeutics, Inc.
Phase 2
85
California, Florida, Iowa, Maryland, New Jersey, Ohio, Pennsylvania
2024-01-25
Active, closed
A Study to Evaluate Mavacamten Impact on Myocardial Structure in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy
NCT06112743Cardiomyopathy, Hypertrophic
DrugMavacamten
Bristol-Myers Squibb
Phase 4
63
California, Georgia, Massachusetts, Ohio, Pennsylvania, Texas, Utah
2024-01-24
Recruiting
A Study of ZL-1310 in Subjects With Small Cell Lung Cancer
NCT06179069SCLC
DrugsZL-1310·Atezolizumab·Carboplatin
Zai Lab (Shanghai) Co., Ltd.
Phase 1
339
California, Connecticut, Florida, Michigan, New Jersey, New York, North Carolina, Ohio
2024-01-23
Active, closed
Ph2 Open-label Study of AOC 1044 in Duchenne Muscular Dystrophy Participants With Mutations Amenable to Exon44 Skipping
NCT06244082DMD, Duchenne Muscular Dystrophy, Duchenne, Exon 44
DrugAOC 1044
Avidity Biosciences, Inc.
Phase 2
39
Arkansas, California, Georgia, Massachusetts, Minnesota, North Carolina, Ohio, Texas
2024-01-22
Active, closed
A Trial That Evaluates Disease Characteristics in Hemophilia B Adult Male Participants Receiving Prophylaxis With Standard of Care Factor IX Protein (FIX) Replacement Therapy
NCT05568459Hemophilia B
Regeneron Pharmaceuticals
Observational
11
Colorado, Connecticut, District of Columbia, Florida, Illinois, Indiana, Michigan, Ohio
2024-01-17
Active, closed
A Trial to Learn More About an Experimental Gene Therapy Called Bidridistrogene Xeboparvovec (SRP-9003) as a Possible Treatment for Limb Girdle Muscular Dystrophy 2E/R4
NCT06246513Limb-girdle Muscular Dystrophy
Sarepta Therapeutics, Inc.
Phase 3
17
California, Ohio, Pennsylvania, Virginia
2024-01-15
Active, closed
The HistoSonics Edison™ System for Treatment of Primary Solid Renal Tumors Using Histotripsy (#HOPE4KIDNEY)
NCT05820087Renal Cancer, Tumor, Solid, Kidney Cancer, Tumor
HistoSonics, Inc.
Not applicable
67
California, Connecticut, Florida, Maryland, Massachusetts, New York, Ohio, Texas
2024-01-04
Active, closed
PrProfile: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ION717
NCT06153966Prion Disease
Ionis Pharmaceuticals, Inc.
Phase 1/2
85
Massachusetts, New York, Ohio
2024-01-04
Active, closed
Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa
NCT06079281Hypophosphatasia
DrugALXN1850
Alexion Pharmaceuticals, Inc.
Phase 3
124
Indiana, New York, North Carolina, Ohio, Tennessee
2024-01-03
By invitation
Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)
NCT06191315Wheezing, Asthma
DrugDupilumab
Sanofi
Phase 3
90
Arizona, Florida, Illinois, Kentucky, Minnesota, New York, North Carolina, Ohio
2024-01-03
By invitation
Rollover Study From EXG-US-01
NCT05868499Telomere Biology Disorders With Bone Marrow Failure
DrugEXG34217
Elixirgen Therapeutics, Inc.
Phase 1
12
Ohio
2024-01-01
Recruiting
Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumors
NCT06234397Advanced or Metastatic Solid Tumors
DrugsKeytruda·Pembrolizumab
Hanmi Pharmaceutical Company Limited
Phase 1
216
Florida, Michigan, Ohio, Texas
2023-12-28
Recruiting
A Study of LM-24C5 For Advanced Solid Tumors
NCT06187402Advanced Solid Tumor
DrugLM-24C5
LaNova Medicines Limited
Phase 1/2
49
California, Florida, Indiana, Ohio, Texas, Virginia
2023-12-20
Active, closed
Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis
NCT06046222Eosinophilic Granulomatosis With Polyangiitis, Churg-Strauss Syndrome
NS Pharma, Inc.
Phase 2
45
Colorado, Minnesota, Ohio, Pennsylvania, South Carolina, Tennessee
2023-12-20
Active, closed
REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)
NCT05973773Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
DrugZipalertinib
Taiho Oncology, Inc.
Phase 3
285
Nevada, Ohio, Texas
2023-12-18
Active, closed
A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma
NCT05951959Mantle Cell Lymphoma (MCL)
DrugsAcalabrutinib·Venetoclax·Rituximab
AstraZeneca
Phase 2
108
New Jersey, New York, Ohio, Pennsylvania, Texas
2023-12-13
Active, closed
A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib
NCT05734105GIST
DrugsRipretinib·Sunitinib
Deciphera Pharmaceuticals, LLC
Phase 3
54
California, Connecticut, Florida, Maryland, Massachusetts, Minnesota, New York, Ohio
2023-12-13
Recruiting
A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849
NCT05761223Advanced Solid Tumor
DrugPembrolizumab
1ST Biotherapeutics, Inc.
Phase 1/2
151
Ohio, Texas, Virginia, Washington
2023-12-13
Recruiting
Spartan Stem, World Cup and World Liner Post Market Clinical Follow-up Study
NCT06172569Hip Replacement
Signature Orthopaedics
Observational
200
Ohio
2023-12-08
Recruiting
Phase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squamous Intraepithelial Lesions (Vulvar HSIL, VIN2/3)
NCT06075264Vulvar Diseases, HPV Infection, Vulvar HSIL, Pre-Cancerous Dysplasia
DrugArtesunate
Frantz Viral Therapeutics, LLC
Phase 2
27
Florida, Indiana, Ohio
2023-12-06
Active, closed
A Study of Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Ulcerative Colitis (ROSETTA)
NCT06127043Ulcerative Colitis
DrugRosnilimab
AnaptysBio, Inc.
Phase 2
132
Arizona, California, Florida, Georgia, Illinois, Nevada, New York, Ohio
2023-12-04
Active, closed
Early Feasibility Study Evaluating the 3P-100 Device in Subjects With PH-ILD
NCT05867914Hypertension, Pulmonary, Lung Diseases, Interstitial
Third Pole Therapeutics, Inc.
Not applicable
5
Florida, Ohio, South Carolina
2023-12-04
Recruiting
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
NCT06120283Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer
DrugsBGB-43395·Elacestrant·Letrozole·Fulvestrant
BeOne Medicines
Phase 1
433
Colorado, Florida, Michigan, North Carolina, Ohio, Tennessee, Texas
2023-12-01
Active, closed
Safety and Preliminary Efficacy of BNT314 in Cancer Patients With Malignant Solid Tumors
NCT06150183Advanced Malignant Solid Tumor
DrugBNT314
BioNTech SE
Phase 1
41
Michigan, North Carolina, Ohio
2023-11-30
Active, closed
Safety and Efficacy of the VERTICA® RF Device for the Treatment of ED
NCT06167733Erectile Dysfunction
OHH-MED Medical Ltd
Not applicable
201
California, Florida, Maryland, Ohio, Texas
2023-11-29
Active, closed
An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery
NCT06117891Unresectable Hepatocellular Carcinoma
DrugsTremelimumab·Atezolizumab·Durvalumab·Bevacizumab
Bayer
Observational
300
Maryland, Michigan, New York, Ohio, Pennsylvania
2023-11-27
Recruiting
Study of an Intrathecal Port and Catheter System for Subjects With Spinal Muscular Atrophy
NCT05866419Spinal Muscular Atrophy, Spine Deformity, Scoliosis
Alcyone Therapeutics, Inc
Not applicable
90
Arizona, California, Florida, Illinois, Massachusetts, Michigan, New York, Ohio
2023-11-27
Active, closed
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
NCT06031441Locally Advanced Solid Tumors, Recurrent Solid Tumors, Metastatic Solid Tumors
DrugsTecentriq·Atezolizumab
Genentech, Inc.
Phase 1
65
Alabama, Connecticut, New York, Ohio, Pennsylvania, Tennessee
2023-11-27
Recruiting
Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
NCT05948943Lymphatic Malformations
DrugAlpelisib
Novartis Pharmaceuticals
Phase 2/3
232
California, District of Columbia, Florida, Massachusetts, Missouri, North Carolina, Ohio, Oregon
2023-11-24
Recruiting
Everglade Stem, World Cup and World Liner Post Market Clinical Follow-up
NCT06153940Hip Disease
Signature Orthopaedics
Observational
200
Ohio
2023-11-22
Active, closed
Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations
NCT06160752Locally Advanced Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma, Solid Tumor, Metastatic Cholangiocarcinoma
Tyra Biosciences, Inc
Phase 1
40
California, Massachusetts, Ohio, Texas
2023-11-22
Recruiting
Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Non-Hodgkin Lymphoma
NCT05312801Lymphoma, Non-Hodgkin Lymphoma, B-Cell
DrugBaff Car-T
Luminary Therapeutics
Phase 1
20
Ohio
2023-11-21
Recruiting
A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
NCT06173518Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia, Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
DrugAUTO1
Autolus Limited
Phase 1
30
Colorado, Illinois, Ohio, Pennsylvania, Texas, Utah
2023-11-16
Active, closed
A Post-Market Study for Long-Term Effectiveness and Safety of the TOMAC System for RLS
NCT06076499Restless Legs Syndrome
Noctrix Health, Inc.
Observational
325
California, Massachusetts, Missouri, Ohio, Pennsylvania, South Carolina
2023-11-15
Recruiting
Efficacy of M640 in Acute Lumbosacral Musculoskeletal Conditions.
NCT06157177Sciatica Acute, Lumbar Spinal Stenosis
DrugMetaxalone
Primus Pharmaceuticals
Phase 4
50
Alabama, California, Florida, Georgia, Michigan, New Mexico, North Carolina, Ohio
2023-11-15
By invitation
A Study Comparing Two Doses of AGTC-501 in Male Participants With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (DAWN)
NCT06275620X-Linked Retinitis Pigmentosa
DrugAGTC-501
Beacon Therapeutics
Phase 2
24
Florida, Massachusetts, Ohio, Oregon, Texas
2023-11-14
Active, closed
A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202
NCT06062420Neoplasms, Head and Neck
DrugsRemzistotug·Nelistotug·Belrestotug·Dostarlimab
GlaxoSmithKline
Phase 2
316
Connecticut, Iowa, Missouri, Ohio, Wisconsin
2023-11-14
Recruiting
A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)
NCT05319353Cytomegalovirus (CMV)
DrugMaribavir
Takeda
Phase 3
80
Delaware, Florida, Illinois, Nebraska, Ohio, Texas
2023-11-13
Active, closed
A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)
NCT05784441Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
Janssen Research & Development, LLC
Phase 1
21
Iowa, Kentucky, Minnesota, New Jersey, Ohio, Pennsylvania, Texas
2023-11-06
Recruiting
Phase 1 Study of Intratumoral Administration of VAX014 With Expansion in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors
NCT05901285Advanced Solid Tumor, Advanced Solid Tumors Appropriate for Treatment With Either Nivolumab or Pembrolizumab
Vaxiion Therapeutics
Phase 1
48
Arizona, Colorado, District of Columbia, Massachusetts, New Hampshire, New Jersey, Ohio
2023-11-02
Recruiting
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
NCT05970497Cancer, Melanoma Stage III, Melanoma Stage IV, Cutaneous Melanoma
DrugsKB707·Opdualag·Keytruda·Pembrolizumab
Krystal Biotech, Inc.
Phase 1/2
240
California, Florida, Indiana, Michigan, Nebraska, New Jersey, New York, Ohio
2023-10-31
Recruiting
Prospective Multi-Center Trial for FemBloc Permanent Birth Control
NCT05977751Contraception
Femasys Inc.
Not applicable
573
Arizona, California, Georgia, Idaho, New York, Ohio, Tennessee, Utah
2023-10-31
Recruiting
Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
NCT05892614Interstitial Lung Disease
aTyr Pharma, Inc.
Phase 2
25
California, Florida, Illinois, Louisiana, New York, Ohio, Oklahoma, South Carolina
2023-10-26
Active, closed
A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
NCT05873686Advanced Solid Tumor, NSCLC (Non-small Cell Lung Cancer), Renal Cancer, Mesothelioma
DrugNXP900
Nuvectis Pharma, Inc.
Phase 1
140
Arizona, California, Colorado, Florida, Illinois, Minnesota, New York, Ohio
2023-10-26
Recruiting
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
NCT06119685NHL, Multiple Myeloma, Blood Cancer, Refractory Non-Hodgkin Lymphoma
DrugsMesna·Darzalex·Isatuximab·Aldesleukin
Indapta Therapeutics, INC.
Phase 1/2
128
California, Florida, Georgia, Minnesota, New York, North Carolina, Ohio, Oregon
2023-10-25
Recruiting
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
NCT06060613Tumor Skin, Metastatic Melanoma, Melanoma, Lung Cancer
Obsidian Therapeutics, Inc.
Phase 1/2
254
California, Florida, Kentucky, New York, Ohio, Pennsylvania, Texas
2023-10-25
Recruiting
Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS
NCT06096974Advanced Solid Tumors
Shanghai YingLi Pharmaceutical Co. Ltd.
Phase 1
60
Ohio, Texas, Utah
2023-10-24
Active, closed
Shoulder iD™ Primary Reversed Glenoid Outcomes Clinical Study
NCT05868148Rotator Cuff Tears, Rheumatoid Arthritis Shoulder, Osteoarthritis Shoulder, Avascular Necrosis of the Head of Humerus
Stryker Trauma and Extremities
Observational
200
California, Ohio, Texas, Virginia
2023-10-20
Active, closed
Nerve Protection Evaluation: Revision Cubital Tunnel Syndrome Decompression
NCT06117501Recurrent Cubital Tunnel Syndrome, Recalcitrant Cubital Tunnel Syndrome
Axogen Corporation
Not applicable
20
Florida, Georgia, Indiana, New Mexico, Ohio, Pennsylvania, Utah
2023-10-19
Recruiting
Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age
NCT05871970Lymphatic Malformation
DrugTARA-002
Protara Therapeutics
Phase 2
38
Alabama, Arkansas, Colorado, District of Columbia, Florida, New York, Ohio, Oregon
2023-10-18
Active, closed
A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
NCT06075667Obesity, Overweight
DrugTirzepatide
Eli Lilly and Company
Phase 3
160
Georgia, Idaho, Kansas, Louisiana, Maryland, Minnesota, Missouri, Ohio
2023-10-16
Active, closed
J-Valve TF Early Feasibility Study
NCT06034028Aortic Valve Disease, Aortic Valve Insufficiency, Aortic Regurgitation
JC Medical, Inc., an affiliate of Edwards Lifesciences LLC
Not applicable
25
Arizona, District of Columbia, Illinois, Louisiana, New York, Ohio, Texas, Washington
2023-10-16
Recruiting
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
NCT06022029Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Lymphoma, Non-Hodgkin
DrugCemiplimab
OncoNano Medicine, Inc.
Phase 1
168
California, Florida, Ohio, Pennsylvania, Texas, Virginia
2023-10-13
Active, closed
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
NCT05891171Advanced Cancer, Advanced Malignancies, Bladder Cancer, Cervical Cancer
DrugsZimberelimab·Fluorouracil·Leucovorin·Oxaliplatin
Arcus Biosciences, Inc.
Phase 1
40
Arizona, Florida, Illinois, Michigan, Minnesota, New Jersey, Ohio, Texas
2023-10-13
By invitation
The Percutaneous Transmural Arterial Bypass -1 Study (Post Approval Registry)
NCT06315023Peripheral Arterial Disease, Symptomatic Femoropopliteal Lesions
Endologix
Observational
450
California, Connecticut, District of Columbia, Florida, Massachusetts, Missouri, New York, Ohio
2023-10-06
Active, closed
GDNF Gene Therapy for Multiple System Atrophy
NCT04680065Multiple System Atrophy
DrugAAV2-GDNF gene therapy
Brain Neurotherapy Bio, Inc.
Phase 1
9
California, Florida, Massachusetts, Michigan, New York, Ohio, Tennessee
2023-10-03
By invitation
A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
NCT06044337Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
DrugLitifilimab
Biogen
Phase 3
306
Alabama, Arizona, California, Michigan, Missouri, North Carolina, Ohio, Pennsylvania
2023-10-03
Active, closed
Expanded Indications in the Pediatric BONEBRIDGE Population
NCT05615649Hearing Loss, Conductive, Hearing Loss, Mixed
Med-El Corporation
Not applicable
36
Colorado, Florida, New Jersey, North Carolina, Ohio, Utah
2023-10-03
Recruiting
Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)
NCT06087653Multiple Myeloma
DrugsLenalidomide·Dexamethasone
Starton Therapeutics, Inc
Phase 1/2
24
North Carolina, Ohio
2023-10-02
Recruiting
Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.
NCT05609630Juvenile Idiopathic Arthritis
DrugsUpadacitinib·Tocilizumab
AbbVie
Phase 3
90
Arizona, District of Columbia, New York, North Carolina, Ohio, Oregon
2023-10-02
Active, closed
Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG
NCT05610891High-Grade Glioma
DrugCLR 131
Cellectar Biosciences, Inc.
Phase 1
50
California, New York, Ohio, Pennsylvania, Texas, Wisconsin
2023-10-01
Recruiting
A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies
NCT05957367GIST
DrugRipretinib
Deciphera Pharmaceuticals, LLC
Phase 1/2
94
California, Florida, Massachusetts, Michigan, Missouri, New York, Ohio, Oregon
2023-09-28
Active, closed
A Study of ADRX-0706 in Select Advanced Solid Tumors
NCT06036121Solid Tumors, Triple Negative Breast Cancer (TNBC), Urothelial Cancer, Cervical Cancer
Adcentrx Therapeutics
Phase 1
144
California, Florida, Michigan, Ohio, Oklahoma, Tennessee, Texas, Utah
2023-09-26
Active, closed
A Long-term Study of STAR-0215 in Participants With Hereditary Angioedema
NCT06007677Hereditary Angioedema
DrugNavenibart
Astria Therapeutics, Inc.
Phase 2
56
Alabama, Arizona, Arkansas, California, Maryland, Massachusetts, Missouri, Ohio
2023-09-26
Active, closed
A Study of AT-02 in Subjects With Systemic Amyloidosis.
NCT05951049Amyloidosis; Systemic
Attralus, Inc.
Phase 2
120
Kansas, Ohio, Oregon, Pennsylvania
2023-09-21
By invitation
An Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007
NCT06075537Mucopolysaccharidosis II
DrugTividenofusp alfa
Denali Therapeutics Inc.
Phase 2/3
99
California, Illinois, New Jersey, North Carolina, Ohio, Pennsylvania, Texas, Utah
2023-09-20
Recruiting
Efficacy in Controlling Myopia in Young Children Using a Novel Spectacle Lens
NCT06034327Myopia, Juvenile Myopia, Myopia Progression
SightGlass Vision, Inc.
Not applicable
150
California, Florida, Georgia, Illinois, Kansas, Massachusetts, Missouri, Ohio
2023-09-18
Recruiting
Gene Therapy Trial for Otoferlin Gene-mediated Hearing Loss
NCT05821959Sensorineural Hearing Loss, Bilateral
Eli Lilly and Company
Phase 3
48
California, Iowa, Massachusetts, Ohio, Pennsylvania, Tennessee
2023-09-15
Recruiting
Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
NCT06034275Acute Myeloid Leukemia, B-cell Acute Lymphoblastic Leukemia, High-risk Myelodysplastic Syndrome
Vincerx Pharma, Inc.
Phase 1
36
Alabama, Ohio, Tennessee, Texas, Washington
2023-09-13
Recruiting
A Multicenter, Postmarket Surveillance Study of Subjects With the Canary canturioTM te Tibial Extension
NCT06040827Knee Osteoarthritis
Canary Medical
Observational
626
Arkansas, Florida, Georgia, Indiana, Ohio, South Carolina
2023-09-12
Active, closed
Cryoablation for Monomorphic Ventricular Tachycardia
NCT05675865Sustained VT
Adagio Medical
Not applicable
206
Arizona, California, Maryland, Massachusetts, Michigan, New York, Ohio, Pennsylvania
2023-09-11
Active, closed
Clairleafᵀᴹ: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This Medicine
NCT05846230Bronchiectasis
DrugVerducatib
Boehringer Ingelheim
Phase 2
268
California, Florida, Kansas, New York, Ohio, South Carolina, Texas
2023-09-08
Active, closed
NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration
NCT05984927Age-Related Macular Degeneration
Elisigen, Inc.
Phase 1/2
20
Ohio
2023-09-08
Active, closed
A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma
NCT05664243Glioblastoma
In8bio Inc.
Phase 1/2
4
Alabama, Florida, Kentucky, Ohio
2023-09-08
Recruiting
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
NCT06040541Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors
DrugsRMC-9805·Cetuximab
Revolution Medicines, Inc.
Phase 1
604
California, Connecticut, Florida, Maryland, Massachusetts, New York, North Carolina, Ohio
2023-09-07
Recruiting
Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis
NCT05964829Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Chronic Progressive
Cionic, Inc.
Not applicable
14
Ohio
2023-09-04
Recruiting
A Registry Study to Assess Photobiomodulation in Dry Age-Related Macular Degeneration (GLOBALIGHT)
NCT06351605Dry Age-related Macular Degeneration
LumiThera, Inc.
Observational
500
California, Ohio, South Carolina, Texas, Washington
2023-09-01
Recruiting
SPEARHEAD-3 Pediatric Study
NCT05642455Synovial Sarcoma, Malignant Peripheral Nerve Sheath Tumor (MPNST), Neuroblastoma (NBL), Osteosarcoma
USWM CT, LLC
Phase 1/2
20
California, Maryland, Massachusetts, Missouri, New York, North Carolina, Ohio, Pennsylvania
2023-09-01
Recruiting
Glaukos® iStent Infinite Trabecular Micro-Bypass System in Subjects With Mild to Moderate Primary Open-angle Glaucoma
NCT06057051Glaucoma
Glaukos Corporation
Not applicable
245
Ohio
2023-09-01
By invitation
HELIOS: Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants With EPP or XLP
NCT05883748Erythropoietic Protoporphyria
DrugBitopertin
Disc Medicine, Inc
Phase 2/3
230
Alabama, California, Florida, Massachusetts, New York, North Carolina, Ohio, Pennsylvania
2023-08-31
Active, closed
Pediatric Patients Aged 1 to 6 Years With APDS
NCT05693129APDS
DrugLeniolisib
Pharming Technologies B.V.
Phase 3
16
California, Maryland, Ohio, Texas
2023-08-30
Recruiting
Study of AVZO-021 in Patients With Advanced Solid Tumors
NCT05867251Advanced Solid Tumor, HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer, CCNE1 Amplification
DrugsAVZO-021·Sacituzumab Govitecan·Abemaciclib·Ribociclib
Avenzo Therapeutics, Inc.
Phase 1/2
430
Connecticut, Florida, New York, Ohio, Oklahoma, Oregon, Pennsylvania, Texas
2023-08-30
Recruiting
A Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN)
NCT06064890Frontotemporal Dementia, FTD, FTD-GRN, Dementia, Frontotemporal
AviadoBio Ltd
Phase 1/2
18
Ohio, Tennessee, Texas
2023-08-30
Active, closed
A Prospective Imaging Study of the Integrated TrueBeam-HyperSight CBCT System
NCT05975619Head and Neck Cancer, Thoracic Cancer, Abdominal Cancer, Pelvic Cancer
Varian, a Siemens Healthineers Company
Not applicable
40
Ohio
2023-08-29
Recruiting
A Registry of Cardiac PET and CardioFlux Magnetocardiography in Patients With Suspected Coronary Ischemia.
NCT05868902Coronary; Ischemic
Genetesis Inc.
Observational
300
Ohio
2023-08-28
Active, closed
A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma
NCT05929235Advanced Urothelial Carcinoma, Oral Drug Administration, Open Label
DrugsKeytruda·Pembrolizumab
Flare Therapeutics Inc.
Phase 1
120
California, Connecticut, Florida, Illinois, Massachusetts, New York, North Carolina, Ohio
2023-08-24
Active, closed
TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3)
NCT05862324Metastatic Solid Tumor
Triumvira Immunologics, Inc.
Phase 1/2
113
California, Florida, Massachusetts, New York, Ohio, Texas
2023-08-23
Recruiting
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
NCT05785741Advanced Solid Tumor
DrugsDB-1310·Osimertinib·Trastuzumab·Capecitabine
DualityBio Inc.
Phase 1/2
1,000
California, Florida, Georgia, Massachusetts, Michigan, New Jersey, Ohio, Tennessee
2023-08-17
Recruiting
CERAMENT G Device Registry
NCT06010433Chronic Osteomyelitis, Fracture Related Infection, Diabetic Foot Osteomyelitis
BONESUPPORT AB
Observational
100
California, North Carolina, Ohio
2023-08-17
By invitation
Prediction of REsponse to Depression Interventions Using Clinical and TD-fNIRS Measurements
NCT06002100Depression, Major Depressive Disorder
Kernel
Observational
540
California, Ohio, Washington
2023-08-14
Recruiting
Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM
NCT05836259Hypertrophic Cardiomyopathy
Tenaya Therapeutics
Phase 1/2
30
California, Georgia, Massachusetts, Minnesota, Ohio, Oregon, Pennsylvania, Texas
2023-08-10
Active, closed
Use of DurAVR™ THV System in Subjects With Severe Aortic Stenosis: Early Feasibility Study
NCT05712161Aortic Stenosis, Symptomatic Aortic Stenosis, Severe Aortic Valve Stenosis, Aortic Valve Calcification
Anteris Technologies Ltd.
Not applicable
15
Arizona, Michigan, New York, Ohio
2023-08-07
Active, closed
A Phase 1/Phase 2 Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of a Single Intravenous Administration of SAR444836 in Adult Participants With Phenylketonuria
NCT05972629Phenylketonuria
Sanofi
Phase 1/2
32
California, Colorado, Florida, Ohio, Pennsylvania, South Carolina, Texas
2023-08-07
Recruiting
A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.
NCT05967689Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
DrugZipalertinib
Taiho Oncology, Inc.
Phase 2
220
Alabama, California, Massachusetts, Nevada, New Jersey, New York, Ohio, Tennessee
2023-07-31
Recruiting
Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma
NCT05879367Glioblastoma, IDH-wildtype, Glioblastoma, Glioblastoma Multiforme, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
DrugsDFMO·Eflornithine·Temodar·Temozolomide
Orbus Therapeutics, Inc.
Phase 1
66
Alabama, Michigan, New York, North Carolina, Ohio, Rhode Island, Texas, Utah
2023-07-24
Active, closed
Blinded Efficacy and Safety Study of CAL02 IV Plus SOC in Subjects With Severe Community-Acquired Bacterial Pneumonia
NCT05776004Pneumonia, Bacterial
Eagle Pharmaceuticals, Inc.
Phase 2
276
California, Florida, Illinois, Nebraska, North Carolina, Ohio, Texas
2023-07-22
Recruiting
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
NCT05974150Breast Cancer, Lung Cancer, Multiple Myeloma, Ovarian Cancer
Carevive Systems, Inc.
Observational
25
Connecticut, Illinois, North Carolina, Ohio
2023-07-19
Recruiting
A Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase Alfa/Miglustat in IOPD Subjects Aged 0 to <18
NCT04808505Glycogen Storage Disease Type II Infantile Onset
DrugsCipaglucosidase alfa·Miglustat
Amicus Therapeutics
Phase 3
36
Florida, Georgia, North Carolina, Ohio, Pennsylvania, Utah
2023-07-18
Recruiting
Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.
NCT05808634Advanced Adenocarcinoma
BioAtla, Inc.
Phase 1
168
California, Connecticut, Illinois, Michigan, Ohio, Washington
2023-07-14
By invitation
Real-World Registry - The Vivally® System
NCT06085846Urinary Incontinence, Urinary Urge Incontinence
Avation Medical, Inc.
Observational
5,000
Ohio
2023-07-14
Active, closed
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
NCT05945823Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer, Esophageal Adenocarcinoma, Esophageal Squamous Cell Cancer, Siewert Type 1 GEJ Cancer
DrugsFutibatinib·Leucovorin·Irinotecan·Adrucil
Taiho Oncology, Inc.
Phase 2
53
California, Colorado, Florida, Michigan, New Jersey, New York, Ohio, Pennsylvania
2023-07-13
Recruiting
A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer
NCT05710848Non-muscle-invasive Bladder Cancer
SURGE Therapeutics
Phase 1/2
75
Arizona, Arkansas, California, Florida, Maryland, Massachusetts, Michigan, Ohio
2023-07-11
Active, closed
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up
NCT05677451Chronic Spontaneous Urticaria
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 3
100
California, Florida, Idaho, Illinois, Kentucky, Ohio, Oklahoma, Pennsylvania
2023-07-11
Recruiting
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
NCT05985655Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC), Platinum-resistant High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC)
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
Phase 1/2
230
California, Michigan, New York, Ohio, Texas, Utah
2023-07-06
Recruiting
Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement
NCT05727176Advanced Cholangiocarcinoma, FGFR2 Fusions, Gene Rearrangement
DrugFutibatinib
Taiho Oncology, Inc.
Phase 2
120
California, Florida, Michigan, Ohio, Texas
2023-07-05
Recruiting
A Study of DB-OTO, an Adeno-Associated Virus (AAV) Based Gene Therapy, in Children/Infants, Adolescents and Adults With Hearing Loss Due to Otoferlin Mutations
NCT05788536Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF)
Regeneron Pharmaceuticals
Phase 1/2
36
California, Florida, Massachusetts, New York, Ohio, Washington, Wisconsin
2023-06-27
Active, closed
ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)
NCT05601752Ovarian Cancer
USWM CT, LLC
Phase 2
66
Arizona, California, Georgia, Michigan, New Jersey, Ohio, Oklahoma, South Dakota
2023-06-26
Active, closed
A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors
NCT05627063Solid Tumor
Abbisko Therapeutics Co, Ltd
Phase 1
169
California, Michigan, Nevada, Ohio
2023-06-26
Active, closed
The ENERGY Study: Evaluation of Safety and Tolerability of INZ-701 in Infants With ENPP1 Deficiency or ABCC6 Deficiency
NCT05734196Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency, Autosomal Recessive Hypophosphatemic Rickets, Generalized Arterial Calcification of Infancy, ATP-Binding Cassette Subfamily C Member 6 Deficiency
DrugINZ-701
Inozyme Pharma
Phase 1
16
California, Ohio, Pennsylvania
2023-06-25
Recruiting
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
NCT05780034Relapsed/Refractory B-cell Malignancies
Accutar Biotechnology Inc
Phase 1
60
Colorado, Florida, North Carolina, Ohio, Oregon, Tennessee, Texas, Washington
2023-06-20
Active, closed
Early Feasibility Study of the NORM™ System in Heart Failure Patients (FUTURE-HFII)
NCT05763407Heart Failure
Foundry Innovation & Research 1, Limited (FIRE1)
Not applicable
25
Minnesota, New York, North Carolina, Ohio, South Carolina, Texas
2023-06-19
Recruiting
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
NCT05714839Multiple Myeloma
DrugsBelantamab mafodotin·Pomalidomide·Dexamethasone
GlaxoSmithKline
Phase 1/2
123
Arizona, California, Florida, Massachusetts, Michigan, North Carolina, Ohio, Tennessee
2023-06-14
Active, closed
Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies
NCT05753501Hematologic Cancer
DrugVenetoclax
AbbVie
Phase 1
135
Arizona, California, Colorado, Illinois, Massachusetts, New Jersey, New York, Ohio
2023-06-09
Recruiting
A Registry to Gather Real World Use Data on the Cerene® Cryotherapy Device
NCT05922657Heavy Menstrual Bleeding, Abnormal Uterine Bleeding, Menorrhagia
Channel Medsystems
Observational
300
New Jersey, Ohio
2023-06-09
Recruiting
IMPACT - AndHealth Autoimmune Research Registry
NCT05883371Arthritis, Rheumatoid, Arthritis, Psoriatic, Psoriasis, Ankylosing Spondylitis
AndHealth
Observational
2,500
Ohio
2023-06-08
Recruiting
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
NCT05797168Ovarian Cancer, Lung Adenocarcinoma, Endometrial Cancer, Lung Squamous Cell Carcinoma
DrugsPalacaparib·Torvutatug samrotecan·Saruparib·Paraplatin
AstraZeneca
Phase 1/2
622
California, Colorado, Kentucky, Massachusetts, Michigan, Ohio, Oregon, Rhode Island
2023-06-05
Recruiting
Observational Study of THC Concentrations in Acute Cannabis-induced CNS Depression
NCT06017622Acute Cannabis-induced CNS Depression
Anebulo Pharmaceuticals
Observational
36
Massachusetts, Ohio, Oregon
2023-06-01
Recruiting
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
NCT05824975Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS), Platinum-resistant Ovarian Cancer (PROC)
DrugsEribulin·Trastuzumab deruxtecan·Doxorubicin·Keytruda
GI Innovation, Inc.
Phase 1/2
358
Arizona, Florida, Minnesota, New York, Ohio
2023-05-30
Active, closed
A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)
NCT05885464Lymphoblastic Lymphoma, T-Cell Lymphoblastic Leukemia/Lymphoma, Lymphoblastic Leukemia
Beam Therapeutics Inc.
Phase 1/2
5
California, Colorado, Illinois, Kansas, Massachusetts, Ohio, Oregon, Pennsylvania
2023-05-25
Recruiting
Safety and Tolerability of Open-Labeled Iloperidone in Adolescents
NCT05648591Schizophrenia, Bipolar I Disorder
DrugIloperidone
Vanda Pharmaceuticals
Phase 4
100
Alabama, Arkansas, Colorado, Georgia, North Carolina, Ohio, Washington
2023-05-24
Active, closed
Novel α2-Antiplasmin Inactivation for Lysis of Intravascular Thrombi (NAIL-IT) Trial
NCT05408546Pulmonary Embolism
DrugTS23
Translational Sciences, Inc.
Phase 2
64
Arizona, California, Georgia, Maryland, Massachusetts, Michigan, North Carolina, Ohio
2023-05-24
Active, closed
Study of PYX-106 in Solid Tumors
NCT05718557Solid Tumor
Pyxis Oncology, Inc
Phase 1
47
Arizona, California, Colorado, Georgia, Illinois, Massachusetts, Ohio, Rhode Island
2023-05-23
Recruiting
Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma
NCT05734066Refractory Ewing Sarcoma, Relapsed Ewing Sarcoma, Ewing Sarcoma
DrugLurbinectedin
Jazz Pharmaceuticals
Phase 1/2
60
California, District of Columbia, Florida, Georgia, Maryland, Michigan, New York, Ohio
2023-05-23
Recruiting
A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]
NCT05895786Myositis
Pfizer
Phase 3
318
Arizona, California, Florida, Massachusetts, Missouri, New York, Ohio, Oklahoma
2023-05-20
Recruiting
MASA Valve Early Feasibility Study
NCT05452720Tetrology of Fallot, Pulmonary Stenosis, Truncus Arteriosus, Transposition of Great Vessels
PECA Labs
Not applicable
10
Illinois, Massachusetts, Ohio, Pennsylvania, Texas
2023-05-18
Recruiting
Stereotactic Adaptive Radiation Therapy of Borderline Resectable Pancreatic Cancer an Individualized Approach
NCT05764720Pancreatic Cancer
Varian, a Siemens Healthineers Company
Not applicable
134
Alabama, California, Missouri, Ohio
2023-05-14
Active, closed
A Study to Evaluate ATP150/ATP152/ATP162, VSV-GP154 and Ezabenlimab in Patients With Pancreatic Ductal Adenocarcinoma
NCT05846516Pancreatic Ductal Adenocarcinoma
DrugEzabenlimab
Boehringer Ingelheim
Phase 1
59
California, Colorado, Florida, Michigan, New York, Ohio, Texas, Virginia
2023-05-11
Recruiting
XTX301 in Patients With Advanced Solid Tumors
NCT05684965Advanced Solid Tumor
Xilio Development, Inc.
Phase 1/2
358
California, Connecticut, Minnesota, Missouri, New Jersey, Ohio, Pennsylvania, Texas
2023-05-11
By invitation
G7 Freedom Constrained Vivacit-E Liners
NCT05587244Osteoarthritis, Hip, Rheumatoid Arthritis, Non-Union Fracture, Trochanteric Fractures
Zimmer Biomet
Not applicable
202
Alabama, California, Florida, New Jersey, Ohio, Tennessee, Texas, Utah
2023-05-08
Recruiting
Study to Assess Safety and Efficacy of Vactosertib in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma
NCT05588648Osteosarcoma
MedPacto, Inc.
Phase 1/2
48
Ohio
2023-05-01
Active, closed
Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)
NCT05804045Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath
DrugPimicotinib
Abbisko Therapeutics Co, Ltd
Phase 3
94
California, Michigan, New York, Ohio, Texas, Washington
2023-04-27
Active, closed
Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies
NCT05665062CLL/SLL, NHL, Mantle Cell Lymphoma, Follicular Lymphoma
DrugsSTK-009·SYNCAR-001·Fludarabine·Cyclophosphamide
Synthekine
Phase 1
36
California, New York, Ohio
2023-04-23
Recruiting
Cardiac RADIoablation Versus Repeat Catheter Ablation: a Pivotal Randomized Clinical Trial Evaluating Safety and Efficacy for Patients With High-risk Refractory Ventricular Tachycardia (RADIATE-VT)
NCT05765175Tachycardia, Ventricular
Varian, a Siemens Healthineers Company
Not applicable
380
California, Connecticut, Massachusetts, Minnesota, Missouri, Ohio, Pennsylvania, South Carolina
2023-04-21
Active, closed
Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies
NCT05783622Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Colorectal Carcinoma
Janux Therapeutics
Phase 1
130
California, Georgia, Illinois, Michigan, Missouri, New York, North Carolina, Ohio
2023-04-19
Recruiting
Pounce™ Thrombectomy System Retrospective Registry
NCT05868161Peripheral Arterial Disease, Acute Limb Ischemia
SurModics, Inc.
Observational
500
Illinois, Indiana, Louisiana, Minnesota, Ohio, South Carolina, South Dakota, Tennessee
2023-04-18
Active, closed
A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer
NCT05645692Urothelial Cancer
DrugsTobemstomig·Tiragolumab·Atezolizumab
Hoffmann-La Roche
Phase 2
204
Ohio, Texas
2023-04-13
Recruiting
Study of SGR-1505 in Mature B-Cell Neoplasms
NCT05544019Mature B-Cell Neoplasm, Non Hodgkin Lymphoma, DLBCL, Waldenstrom Macroglobulinemia
Schrödinger, Inc.
Phase 1
98
Arizona, Delaware, Florida, Massachusetts, New Jersey, New York, North Carolina, Ohio
2023-04-10
Active, closed
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma
NCT05692180Asthma
DrugBenralizumab
AstraZeneca
Phase 3
94
California, Florida, Kentucky, Louisiana, Missouri, New Jersey, New York, Ohio
2023-04-05
Recruiting
A Study of GEn-1124 in Subjects With Acute Respiratory Distress Syndrome (ARDS)
NCT05795465Respiratory Distress Syndrome, Acute
GEn1E Lifesciences
Phase 2
52
District of Columbia, Kansas, Maryland, Mississippi, Missouri, New Jersey, New York, Ohio
2023-04-04
Recruiting
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
NCT05856981Solid Tumor, Adult, Metastatic Solid Tumor, Refractory Cancer, CRC, Colorectal Cancer
DrugsKeytruda·Pembrolizumab
Sairopa B.V.
Phase 1
130
Michigan, Missouri, Ohio, Virginia
2023-04-03
Active, closed
ALT-FLOW II Trial of the Edwards APTURE Transcatheter Shunt System
NCT05686317Heart Failure
Edwards Lifesciences
Not applicable
100
California, Illinois, Kansas, Minnesota, New York, Ohio, Oklahoma, Oregon
2023-04-01
Active, closed
PerQseal® Clinical Study
NCT05653336Percutaneous Large Hole Vascular Closure
Vivasure Medical Limited
Not applicable
149
Arizona, California, Maine, New Jersey, New York, Ohio, Pennsylvania, Texas
2023-03-30
Recruiting
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
NCT05735080Breast Cancer, Breast Cancer Metastatic, Hormone Receptor Positive Tumor, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
DrugsAbemaciclib·Fulvestrant
Incyclix Bio
Phase 1/2
150
Florida, Georgia, Indiana, Massachusetts, Michigan, New York, North Carolina, Ohio
2023-03-28
Recruiting
A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GAlette); Adaptive Optics (AO) Retinal Imaging Substudy in Association With Study GR44251
NCT05626114Geographic Atrophy
DrugOpRegen
Genentech, Inc.
Phase 2
60
California, Florida, Maryland, Missouri, Nevada, North Carolina, Ohio, Pennsylvania
2023-03-23
Active, closed
A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma
NCT04485949Glioblastoma
Imvax
Phase 2
99
Florida, Massachusetts, Michigan, New Hampshire, New Jersey, New York, North Carolina, Ohio
2023-03-20
By invitation
G7 Dual Mobility With Vivacit-E or Longevity PMCF
NCT05548972Hip Osteoarthritis, Rheumatoid Arthritis, Joint Diseases, Avascular Necrosis
Zimmer Biomet
Not applicable
358
Arkansas, Colorado, New Jersey, New York, Ohio, Oregon
2023-03-20
Active, closed
Study of Novel Treatment Combinations in Patients With Lung Cancer
NCT05633667Lung Cancer, Advanced or Metastatic Non-Small-Cell Lung Cancer, Resectable Non-Small-Cell Lung Cancer
DrugsDomvanalimab·Zimberelimab·Sacituzumab Govitecan·Nab-paclitaxel
Gilead Sciences
Phase 2
192
Arizona, Indiana, Kentucky, Missouri, Ohio, Oregon
2023-03-16
Recruiting
A Study of ASP1002 in Adults for Treatment of Solid Tumors
NCT05719558Advanced Solid Tumors
DrugsRamucirumab·Trifluridine/Tipiracil·Fluorouracil·Leucovorin
Astellas Pharma Global Development, Inc.
Phase 1
798
Connecticut, Florida, Iowa, Kentucky, Michigan, Minnesota, New York, Ohio
2023-03-13
Active, closed
Safety and Effectiveness of the Globe® Pulsed Field System for Treating Patients With Symptomatic Paroxysmal or Persistent Atrial Fibrillation
NCT05462145Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation
Kardium Inc.
Not applicable
549
Alabama, Arkansas, California, Florida, Maryland, Michigan, New York, Ohio
2023-03-09
Active, closed
FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases in the Thorax
NCT05524064Bone Metastases in the Thorax
Varian, a Siemens Healthineers Company
Not applicable
10
Illinois, Ohio
2023-03-08
Active, closed
Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors
NCT05651022Solid Tumor, Adult, HCC - Hepatocellular Carcinoma, CRC (Colorectal Cancer), Pancreatic Adenocarcinoma
DrugTislelizumab
Indaptus Therapeutics, Inc
Phase 1/2
120
California, Georgia, Michigan, Missouri, New Jersey, New York, Ohio, Pennsylvania
2023-02-28
Recruiting
VIrtual STudy in Achondroplasia for the US (VISTA)
NCT06168201Achondroplasia
BioMarin Pharmaceutical
Observational
170
California, Maryland, North Carolina, Ohio, South Dakota, Texas, Wisconsin
2023-02-21
Recruiting
Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Pediatric ORION-16, ORION-13, ORION-20, or ORION-19 Studies
NCT05682378Heterozygous or Homozygous Familial Hypercholesterolemia
DrugInclisiran
Novartis Pharmaceuticals
Phase 3
195
Florida, New York, Ohio, Pennsylvania, Utah
2023-02-10
Recruiting
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
NCT05722418Relapsed/Refractory Multiple Myeloma
DrugsFludarabine·Cyclophosphamide
Caribou Biosciences, Inc.
Phase 1
50
Alabama, Colorado, Florida, Kentucky, New Jersey, New York, North Carolina, Ohio
2023-02-06
Active, closed
Pilot/Pivotal Study of DBS+Rehab After Stroke
NCT05701280Stroke, Upper Extremity Paresis
Enspire DBS Therapy, Inc.
Not applicable
202
Arizona, Maryland, Massachusetts, Minnesota, New York, Ohio, Pennsylvania, Rhode Island
2023-02-03
Active, closed
A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia
NCT05662319Hemophilia
DrugsAntithrombin·Clotting factor concentrates·Fitusiran
Sanofi
Phase 3
91
California, Minnesota, New Jersey, New York, Ohio, Pennsylvania, Texas
2023-02-01
Active, closed
A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia
NCT05520567Acute Myeloid Leukemia (AML), FLT3-mutated Acute Myeloid Leukemia
DrugsXospata·Gilteritinib·Venclexta·Azacitidine
Astellas Pharma Global Development, Inc.
Phase 1/2
70
California, Colorado, Florida, Illinois, Maryland, New York, North Carolina, Ohio
2023-01-31
Recruiting
Non-interventional Study of Seroprevalence of Pre-existing Antibodies Against Adenovirus-associated Virus Vector (AAV9) and the Progression of Disease in Patients With Plakophilin 2 (PKP2)-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)
NCT06311708Arrhythmogenic Right Ventricular Cardiomyopathy
Tenaya Therapeutics
Observational
200
California, Colorado, Maryland, Massachusetts, Minnesota, New York, Ohio, South Carolina
2023-01-31
Active, closed
Observational Lung Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform (ELEPHAS-01)
NCT05478538NSCLC (Non-small Cell Lung Cancer), Metastatic NSCLC - Non-Small Cell Lung Cancer
Elephas
Observational
200
California, Maryland, New York, North Carolina, Ohio, Texas
2023-01-31
Active, closed
Study to Assess SLN124 in Patients With Polycythemia Vera
NCT05499013Polycythemia Vera
Silence Therapeutics plc
Phase 1/2
69
Louisiana, New York, Ohio, Texas
2023-01-26
Recruiting
Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)
NCT05587712Pulmonary Arterial Hypertension
DrugSotatercept
Merck Sharp & Dohme LLC
Phase 2
42
California, Colorado, District of Columbia, Ohio, Pennsylvania, Tennessee, Washington, Wisconsin
2023-01-19
Active, closed
A Clinical Trial to Investigate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults With Multifocal Motor Neuropathy
NCT05405361Multifocal Motor Neuropathy (MMN)
DrugEmpasiprubart
argenx
Phase 2
51
Arizona, Illinois, Minnesota, Ohio, Pennsylvania, Texas
2023-01-18
Active, closed
BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma
NCT05322590Metastatic Colorectal Carcinoma, Neuropathy
Bexion Pharmaceuticals, Inc.
Phase 1/2
195
Alabama, California, Florida, Iowa, Kentucky, Louisiana, New York, Ohio
2023-01-09
Recruiting
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
NCT05592626Advanced Solid Tumors, Genital Neoplasm, Female, Urogenital Neoplasms, Lung Neoplasm
DrugSTAR0602
Marengo Therapeutics, Inc.
Phase 1/2
366
California, Florida, Kansas, Maryland, Massachusetts, Michigan, Ohio, Tennessee
2023-01-04
By invitation
A Long-Term Follow-Up Study in Severe Hemophilia A Subjects Who Received BMN 270 in a Prior BioMarin Clinical Trial (270-401)
NCT05768386Hemophilia A
BioMarin Pharmaceutical
Observational
172
California, Colorado, Florida, Kentucky, Michigan, Missouri, Ohio, Pennsylvania
2023-01-01
Active, closed
Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma
NCT05678673Non-Clear Cell Renal Cell Carcinoma
DrugsSunitinib Malate·Zanzalintinib·Sunitinib·Opdivo
Exelixis
Phase 3
317
California, Colorado, Florida, New York, Ohio, Texas
2023-01-01
Active, closed
Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)
NCT05024773Bladder Carcinoma in Situ (CIS)
Fidia Farmaceutici s.p.a.
Phase 3
130
Arizona, Louisiana, Maryland, Minnesota, Ohio, South Carolina
2022-12-29
Recruiting
Study to Evaluate the Pharmacokinetics and Safety of Pralatrexate in Patients With Advanced Solid Tumor or Hematological Malignancy and Either Normal Hepatic Function or Mild, Moderate, or Severe Hepatic Impairment
NCT07036133Advanced Solid Tumors, Hematologic Malignancies
DrugPralatrexate
Acrotech Biopharma Inc.
Phase 1
24
California, Illinois, Michigan, Ohio
2022-12-28
Recruiting
A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
NCT05645107Hypogammaglobulinemia, Bacterial Infections, B-cell Chronic Lymphocytic Leukemia, Multiple Myleoma
DrugXembify
Grifols Therapeutics LLC
Phase 3
386
Arizona, California, Florida, Maryland, North Carolina, Ohio, South Carolina
2022-12-26
Active, closed
A Gene Transfer Single Dose Study to Evaluate the Safety, Tolerability and Efficacy of SRP-9003 in Non-Ambulatory and Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2E/R4 (Beta-Sarcoglycan [β-SG] Deficiency)
NCT05876780Limb Girdle Muscular Dystrophy
Sarepta Therapeutics, Inc.
Phase 1
6
Ohio, Tennessee
2022-12-19
Recruiting
A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis
NCT05287126Ulcerative Colitis
DrugEtrasimod
Pfizer
Phase 2
36
Arkansas, California, Florida, Illinois, Massachusetts, Michigan, Ohio, Texas
2022-12-16
Active, closed
Study of CHS-114 in Participants With Advanced Solid Tumors
NCT05635643Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma
DrugsCHS-114·Toripalimab
Coherus Oncology, Inc.
Phase 1
87
California, Georgia, Kentucky, Maryland, Michigan, Missouri, Ohio, Tennessee
2022-12-15
Active, closed
Medtronic Hugo™ Robotic Assisted Surgery (RAS) System in Urologic Surgery (Expand URO)
NCT05696444Bladder Cancer, Prostate Cancer, Kidney Cancer, Pelvic Tumor
Medtronic - MITG
Not applicable
144
California, Illinois, New York, North Carolina, Ohio, Washington
2022-12-14
Active, closed
Kaneka Endovascular Embolization and Protection
NCT05563051Aneurysm Cerebral
Kaneka Medical America LLC
Not applicable
164
Michigan, New York, Ohio, Oklahoma
2022-12-13
Active, closed
A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)
NCT05668988Non-small Cell Lung Cancer
DrugsSunvozertinib·Pemetrexed·Carboplatin
Dizal Pharmaceuticals
Phase 3
324
California, Colorado, Florida, New York, Ohio, Oregon, Texas, Virginia
2022-12-13
Active, closed
Clinical Investigation of the da Vinci Surgical System
NCT05682742Thymoma, Mediastinal Tumor, Gynecologic Disease, Gynecologic Cancer
Intuitive Surgical
Not applicable
53
Florida, Michigan, New Jersey, Ohio
2022-12-12
Active, closed
A Clinical Trial in Healthy Volunteers and Volunteers With Recurrent Genital Herpes to Study the Safety, Tolerability, and Immune Responses After Vaccination With an Investigational Vaccine Designed to Prevent Genital Herpes Lesions
NCT05432583Genital Herpes Simplex Type 2
BioNTech SE
Phase 1
318
Arizona, Illinois, North Carolina, Ohio, Pennsylvania
2022-12-08
Active, closed
Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations
NCT05544552Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Solid Tumor, Urothelial Carcinoma
DrugTYRA-300
Tyra Biosciences, Inc
Phase 1/2
310
Massachusetts, New York, North Carolina, Ohio, Tennessee, Washington
2022-11-22
Active, closed
A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)
NCT05456191Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
DrugsAsciminib·ABL001·Nilotinib
Novartis Pharmaceuticals
Phase 3
568
Colorado, Illinois, Minnesota, North Carolina, Ohio, Oregon, Texas, Virginia
2022-11-21
Active, closed
A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC
NCT05611671Inflammatory Bowel Diseases, Colitis, Ulcerative
DrugZotemtegrast
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
Phase 2
280
Arizona, California, Florida, New Jersey, Ohio, Texas
2022-11-21
Recruiting
A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)
NCT05562830Urothelial Carcinoma
DrugsMK-3120·Zilovertamab vedotin·Keytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 1/2
48
California, Colorado, Illinois, Indiana, Missouri, New York, Ohio, Pennsylvania
2022-11-16
Recruiting
A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
NCT05533775Mature B-Cell Non-Hodgkin Lymphoma
DrugsIfosfamide·Glofitamab·Tocilizumab·Obinutuzumab
Hoffmann-La Roche
Phase 1/2
65
Alabama, California, Maryland, Massachusetts, Missouri, New York, Ohio
2022-11-16
Active, closed
LAMBDA 002 (Lung Registry) Study
NCT05170425Lung Transplant Rejection
Natera, Inc.
Observational
154
California, Illinois, Maryland, Michigan, Missouri, New York, Ohio, Texas
2022-11-04
Recruiting
Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment
NCT05363280Small Cell Lung Cancer, Renal Cell Carcinoma (RCC), Non-Small Cell Lung
DrugAL8326
Advenchen Pharmaceuticals, LLC.
Phase 2
80
Alabama, Florida, Illinois, Missouri, Ohio
2022-11-01
Active, closed
Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type
NCT05397639Agitation, Alzheimer's Type Dementia
Suven Life Sciences Limited
Phase 3
375
California, Connecticut, Florida, Illinois, New Jersey, New York, Ohio, South Carolina
2022-11-01
Active, closed
A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease
NCT04020055Fabry Disease
DrugMigalastat HCl
Amicus Therapeutics
Phase 3
14
Georgia, Ohio, Virginia
2022-10-31
Active, closed
A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH
NCT05389449Paroxysmal Nocturnal Hemoglobinuria
DrugDanicopan
Alexion Pharmaceuticals, Inc.
Phase 3
80
California, Illinois, Maryland, Missouri, New York, Ohio, Texas
2022-10-28
Recruiting
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
NCT05208762Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Esophageal Squamous Cell Carcinoma, Triple Negative Breast Neoplasms
DrugsPF-08046054·Keytruda·Pembrolizumab
Seagen, a wholly owned subsidiary of Pfizer
Phase 1
714
Alabama, California, Iowa, Michigan, Ohio, Texas, Utah, Virginia
2022-10-25
Active, closed
Clinical Study of DTX301 AAV-Mediated Gene Transfer for Ornithine Transcarbamylase (OTC) Deficiency
NCT05345171OTC Deficiency
DrugPrednisolone
Ultragenyx Pharmaceutical Inc
Phase 3
37
California, Colorado, Illinois, Ohio
2022-10-18
Active, closed
Phase I Trial to Evaluate VLP Peanut in Healthy and Peanut Allergic Subjects
NCT05476497Peanut Allergy
Allergy Therapeutics
Phase 1
46
Arizona, Florida, Kansas, Massachusetts, Minnesota, Missouri, New York, Ohio
2022-10-17
Active, closed
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer
NCT05502237Non-small Cell Lung Cancer
DrugsDomvanalimab·Zimberelimab·Nab-paclitaxel·Pemetrexed
Gilead Sciences
Phase 3
1,021
California, District of Columbia, Florida, Illinois, North Carolina, Ohio, Oregon, Pennsylvania
2022-10-12
Active, closed
Real World Treatment Experience of Patients With Breast, Lung, or GI Cancer or Multiple Myeloma Using Remote Symptom Monitoring
NCT05587972Breast Cancer, Lung Cancer, Gastrointestinal Cancer, Multiple Myeloma
Carevive Systems, Inc.
Not applicable
100
Ohio
2022-10-06
Recruiting
Met Non Small Cell Cancer Registry (MOMENT)
NCT05376891Cancer
EMD Serono Research & Development Institute, Inc.
Observational
700
Florida, Ohio, Tennessee
2022-10-04
Active, closed
Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab
NCT05206357Non-hodgkin Lymphoma
DrugEpcoritamab
Genmab
Phase 1
17
California, Florida, New York, North Carolina, Ohio, Pennsylvania, Tennessee, Texas
2022-10-04
Active, closed
Study to Assess the Safety of DERMASEAL for Diabetic Foot Ulcers
NCT05586542Foot Ulcer, Diabetic
DrugPlasma
Vitruvian Medical Devices, Inc.
Phase 1
26
California, Florida, Ohio, Texas
2022-10-03
Recruiting
Outcomes Following Combined Adductoplasty™ and Lapiplasty® (MTA3D)
NCT05587569Metatarsus Adductus, Hallux Valgus
Treace Medical Concepts, Inc.
Not applicable
80
Colorado, Iowa, Maine, Missouri, North Carolina, Ohio, Pennsylvania, Texas
2022-09-28
Active, closed
Continued Access Study to Evaluate Performance of the Organ Recovery Systems _LifePort® Liver Transporter System, a Machine Perfusion System, for Liver Transplant (PILOT™_CA)
NCT05574361Liver Transplantation
Organ Recovery Systems, Inc.
Not applicable
385
Illinois, New Jersey, Ohio, Utah
2022-09-19
Active, closed
The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)
NCT05540327Systemic Lupus Erythematosus
DrugEnpatoran
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 2
379
California, Florida, Indiana, Michigan, Minnesota, Ohio, Tennessee
2022-09-16
Recruiting
Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)
NCT05308264Low Risk Myelodysplastic Syndromes
Rigel Pharmaceuticals
Phase 1/2
86
California, Florida, Missouri, New Jersey, New York, North Carolina, Ohio, Texas
2022-09-12
Recruiting
Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial
NCT05334368Hypereosinophilic Syndrome
DrugDepemokimab
GlaxoSmithKline
Phase 3
109
California, Georgia, Massachusetts, Michigan, Minnesota, New York, Ohio, South Carolina
2022-09-06
Active, closed
Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs
NCT04711135Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma, Paraganglioma
DrugsLutetium [177Lu] oxodotreotide/dotatate·Lutathera
Advanced Accelerator Applications
Phase 2
11
Kentucky, Ohio, Pennsylvania
2022-08-31
Recruiting
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
NCT05386108Breast Neoplasms, Brain Neoplasms, Neoplasms by Site, Neoplasms
DrugsElacestrant·Abemaciclib
Stemline Therapeutics, Inc.
Phase 1/2
73
California, Illinois, Massachusetts, Michigan, Ohio, Oregon, Tennessee, Texas
2022-08-31
Recruiting
Use of the REGENETEN™ Bioinductive Implant System in High Grade Partial-thickness Tears
NCT05444465Rotator Cuff Injuries
Smith & Nephew, Inc.
Not applicable
234
Georgia, Illinois, Maryland, Ohio, Pennsylvania, Texas, Wisconsin
2022-08-30
Recruiting
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer
NCT05455619HR+/HER2-negative Breast Cancer, Metastatic Breast Cancer
SynDevRx, Inc.
Phase 1/2
52
California, Florida, Illinois, Michigan, Ohio, Pennsylvania, Tennessee, Texas
2022-08-26
Recruiting
A Prospective Sub-Study of the Global Hypophosphatasia Registry
NCT05234567Hypophosphatasia
DrugAsfotase alfa
Alexion Pharmaceuticals, Inc.
Observational
30
Connecticut, Illinois, Massachusetts, Missouri, New York, Ohio, Pennsylvania, Tennessee
2022-08-25
Recruiting
A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent Surgery
NCT05156983Coagulation Disorder
Takeda
Phase 3
440
Arkansas, California, Colorado, Florida, New Jersey, North Carolina, Ohio, Oklahoma
2022-08-24
Active, closed
Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
NCT05524883Duchenne Muscular Dystrophy (DMD)
DrugZeleciment Rostudirsen
Dyne Therapeutics
Phase 1/2
86
California, Colorado, Georgia, Massachusetts, Ohio, Oregon, Pennsylvania, Utah
2022-08-12
Active, closed
A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
NCT05421663Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse
Janssen Research & Development, LLC
Phase 1/2
166
California, Colorado, Iowa, Kentucky, New Jersey, North Carolina, Ohio, Pennsylvania
2022-08-12
Active, closed
Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation After Thrombus Removal to Yield Benefit in Subacute and Chronic Iliofemoral DVT
NCT04858776Iliofemoral; Thrombosis
Mercator MedSystems, Inc.
Phase 2
60
Connecticut, Florida, Illinois, Louisiana, Maryland, New York, North Carolina, Ohio
2022-08-08
Recruiting
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
NCT05254171Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Stage IV
DrugsAbraxane·Nab-paclitaxel·Gemcitabine
Panbela Therapeutics, Inc.
Phase 2/3
600
Arkansas, California, Connecticut, District of Columbia, Michigan, Minnesota, New York, Ohio
2022-08-08
Active, closed
A Phase 1/2 Study of BA3071 in Patients With Solid Tumors
NCT05180799NSCLC, Melanoma
DrugsPemetrexed·Nivolumab·Pembrolizumab
BioAtla, Inc.
Phase 1/2
320
California, Georgia, Indiana, New Jersey, New York, Ohio, Oregon, Utah
2022-08-03
Active, closed
A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation
NCT05485974Lung Cancer, Non Small Cell Lung Cancer, Colorectal Cancer, Cancer of Pancreas
HUYABIO International, LLC.
Phase 1
44
California, Florida, Michigan, Missouri, Ohio
2022-08-01
Recruiting
CorMatrix Cor TRICUSPID ECM Valve Replacement Study
NCT02397668Tricuspid Valve Disease
Corvivo Cardiovascular, Inc.
Not applicable
78
Alabama, Indiana, Maryland, Ohio
2022-08-01
Active, closed
A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II)
NCT05371613Mucopolysaccharidosis II
DrugsIdursulfase·Tividenofusp alfa
Denali Therapeutics Inc.
Phase 2/3
65
California, Illinois, New Jersey, North Carolina, Ohio, Pennsylvania, Texas, Utah
2022-07-21
Recruiting
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
NCT05361174Unresectable Melanoma, Metastatic Melanoma, Stage III Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Iovance Biotherapeutics, Inc.
Phase 1/2
53
California, Florida, Kansas, Kentucky, New York, Ohio, Pennsylvania, Wisconsin
2022-07-20
Recruiting
Safety and Effectiveness of the HIT Reverse HRS
NCT05357378Degenerative Joint Disease, Osteoarthritis, Hip, Avascular Necrosis of Hip, Traumatic Arthropathy-Hip
Hip Innovation Technology
Not applicable
288
Florida, Maryland, New Jersey, Ohio
2022-07-15
Recruiting
Otoferlin Gene-mediated Hearing Loss Natural History Study
NCT05572073Sensorineural Hearing Loss, Bilateral
Akouos, Inc.
Observational
150
Iowa, Ohio, Pennsylvania, Tennessee
2022-07-14
Active, closed
Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma
NCT05352672Melanoma
DrugsFianlimab·Cemiplimab·Keytruda·Pembrolizumab
Regeneron Pharmaceuticals
Phase 3
1,546
California, Florida, Ohio, Tennessee
2022-07-14
Recruiting
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
NCT05475925LGLL - Large Granular Lymphocytic Leukemia, Primary Cutaneous Gamma-Delta T-Cell Lymphoma, Primary Cutaneous CD8+ Aggressive Epidermotropic T-Cell Lymphoma, Hepatosplenic T-cell Lymphoma
DrugDibotatug
Dren Bio
Phase 1/2
200
Alabama, California, Connecticut, Florida, Massachusetts, New York, Ohio, Pennsylvania
2022-07-13
Recruiting
Tempus Small Cell Lung Cancer Observational Study (Sculptor)
NCT05257551Small Cell Lung Cancer
Tempus AI
Observational
200
California, Colorado, Illinois, Maryland, New Jersey, North Carolina, Ohio, Oklahoma
2022-07-13
Active, closed
A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab
NCT05142696Extensive Stage Small Cell Lung Cancer
Drugs[177Lu]Lu-DOTA-TATE·[68Ga]Ga-DOTA-TATE·Lutathera·Atezolizumab
Novartis Pharmaceuticals
Phase 1/2
55
Florida, Georgia, Kentucky, Missouri, New Jersey, Ohio, Pennsylvania
2022-07-13
Recruiting
Deep Neural Network Stratification for Use Detecting Endometriosis in Women Affected by Chronic Pelvic Pain (EndoCheck)
NCT05245695Endometriosis
Aspira Women's Health
Observational
1,200
Arizona, California, Delaware, Georgia, Indiana, Maryland, New York, Ohio
2022-07-12
Active, closed
PDN Post Market, Multicenter, Prospective, Global Clinical Study
NCT05301816Diabetic Neuropathy, Painful
Nevro Corp
Not applicable
497
Alaska, Michigan, Ohio, Oklahoma, Oregon, Pennsylvania, Virginia
2022-07-05
Active, closed
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
NCT05355701Melanoma, Non-Small-Cell Lung Cancer, Thyroid Cancer, Glioma
DrugsPF-07799933·Binimetinib·Erbitux·Midazolam
Pfizer
Phase 1
103
Arkansas, Colorado, Florida, Massachusetts, Michigan, New Jersey, New York, Ohio
2022-07-05
Active, closed
An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat in Children With Biliary Atresia
NCT05426733Biliary Atresia
DrugOdevixibat
Albireo, an Ipsen Company
Phase 3
180
Colorado, Georgia, Indiana, Massachusetts, Missouri, New York, Ohio, Washington
2022-07-05
Active, closed
Endoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to 11 Years Old With Erosive Esophagitis.
NCT05267613Erosive Esophagitis
DrugNexium
AstraZeneca
Phase 3
53
Alabama, California, Florida, Indiana, Louisiana, New York, Ohio, Wisconsin
2022-07-01
Recruiting
Safety and Device Performance of the Uriprene® Degradable Temporary Ureteral Stent Following Uncomplicated Ureteroscopy
NCT04565795Ureteral Diseases
Adva-Tec
Not applicable
87
Arizona, California, Florida, Ohio
2022-07-01
Recruiting
A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)
NCT04042844Lumbar Disc Disease
BioRestorative Therapies
Phase 2
99
Alabama, California, Colorado, Florida, New York, North Carolina, Ohio, Oklahoma
2022-06-30
Active, closed
SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM
NCT05405166Plasma Cell Myeloma Recurrent
DrugsParacetamol / Acetaminophen·Montelukast·Diphenhydramine·Isatuximab
Sanofi
Phase 3
531
Colorado, Florida, Mississippi, New Jersey, New York, North Carolina, Ohio, South Carolina
2022-06-23
Recruiting
Comprehensive Outcomes for After Cancer Health
NCT05349227Ovarian Cancer, Breast Cancer, Lung Cancer, Gastric Cancer
Pack Health
Not applicable
625
Florida, Massachusetts, Nebraska, New York, Ohio, Texas
2022-06-23
Recruiting
Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays
NCT05234177Colorectal Cancer
Tempus AI
Observational
300
Arkansas, California, Maryland, Missouri, Nebraska, North Carolina, Ohio, Oklahoma
2022-06-21
Recruiting
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
NCT05142189Non-Small Cell Lung Cancer
DrugsBNT116·Gotistobart·Cemiplimab·Osimertinib
BioNTech SE
Phase 1
320
Kentucky, Maryland, Ohio, Texas, Virginia
2022-06-17
Active, closed
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
NCT04970901B-Cell Non-Hodgkin Lymphoma, Relapsed B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma
DrugsLoncastuximab Tesirine·Mosunetuzumab·Polatuzumab Vedotin·Glofitamab
ADC Therapeutics S.A.
Phase 1
154
California, Florida, Georgia, Iowa, Massachusetts, Minnesota, New York, Ohio
2022-06-17
Recruiting
Multicenter Clinical Study of the SING-IMT in Patients with Late-stage AMD
NCT05438732Age-Related Macular Degeneration, Geographic Atrophy
VisionCare, Inc.
Not applicable
125
California, Florida, Massachusetts, Michigan, Nebraska, New Jersey, North Carolina, Ohio
2022-06-16
Recruiting
ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
NCT05405595Advanced/Metastatic Solid Tumors
DrugsADG126·Keytruda·Pembrolizumab
Adagene Inc
Phase 1/2
186
Arizona, California, Florida, Ohio, Texas, Washington
2022-06-15
Active, closed
An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma
NCT05022901Metastatic Ocular Melanoma, Metastatic Uveal Melanoma
Delcath Systems Inc.
Phase 3
30
California, Florida, North Carolina, Ohio, Tennessee
2022-06-10
Active, closed
A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies
NCT05329766Gastrointestinal Tract Malignancies
DrugsQuemliclustat·Domvanalimab·Zimberelimab·Fluorouracil
Arcus Biosciences, Inc.
Phase 2
332
Arizona, California, Connecticut, Florida, Massachusetts, New York, North Carolina, Ohio
2022-06-10
Recruiting
Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib
NCT05280509Myelofibrosis, Primary Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis
DrugsJakavi·Ruxolitinib
Telios Pharma, Inc.
Phase 1/2
70
Alabama, Ohio, Texas
2022-06-09
Active, closed
A Study of mRNA-3745 in Adult and Pediatric Participants With Glycogen Storage Disease Type 1a (GSD1a)
NCT05095727Glycogen Storage Disease
ModernaTX, Inc.
Phase 1/2
15
Connecticut, Massachusetts, North Carolina, Ohio, Pennsylvania, Texas, Utah
2022-06-01
Recruiting
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
NCT05379985Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors
DrugCetuximab
Revolution Medicines, Inc.
Phase 1/2
754
California, Florida, Georgia, Louisiana, Maryland, Massachusetts, New York, Ohio
2022-05-31
Recruiting
A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS
NCT05277168Advanced Solid Tumors
DrugSHR-A1904
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2
83
Florida, Louisiana, Ohio, Rhode Island, South Carolina, Texas
2022-05-30
Active, closed
CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer
NCT05251714Advanced Solid Tumor, Breast Cancer
DrugsCFI-402257·Fulvestrant
Treadwell Therapeutics, Inc
Phase 1/2
44
Ohio, Texas, Utah, Virginia
2022-05-27
Active, closed
A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)
NCT05123703Relapsing-remitting Multiple Sclerosis
DrugsFingolimod·Ocrelizumab
Hoffmann-La Roche
Phase 3
188
California, Colorado, District of Columbia, Maryland, Massachusetts, Missouri, Ohio, Pennsylvania
2022-05-19
Recruiting
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
NCT05039619Lupus Nephritis
DrugsAcetaminophen/paracetamol·Diphenhydramine hydrochloride·Mycophenolate Mofetil·Methylprednisolone
Hoffmann-La Roche
Phase 2
40
California, Colorado, Georgia, Indiana, Louisiana, New Jersey, New York, Ohio
2022-05-12
Recruiting
REMASTer: REcurrent Brain Metastases After SRS Trial
NCT05124912Brain Metastases, Radiation Necrosis, Recurrent Tumor, Recurrent Metastases
Monteris Medical
Not applicable
261
California, Illinois, Maryland, Missouri, North Carolina, Ohio, Wisconsin
2022-05-10
Recruiting
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
NCT04771572Non Hodgkin Lymphoma, Richter Transformation, Multiple Myeloma, T-cell-prolymphocytic Leukemia
Newave Pharmaceutical Inc
Phase 1
100
Illinois, Massachusetts, North Carolina, Ohio, Texas, Utah
2022-05-08
Recruiting
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
NCT05366881Brain Cancer, Breast Cancer, Bladder Cancer, Cervical Cancer
Adela, Inc
Observational
7,000
California, Florida, Georgia, Indiana, Kentucky, Minnesota, Ohio, Oregon
2022-05-03
Active, closed
EDIT-301 for Autologous Hematopoietic Stem Cell Transplant (HSCT) in Participants With Transfusion-Dependent Beta Thalassemia (TDT)
NCT05444894Transfusion Dependent Beta Thalassemia, Hemoglobinopathies, Thalassemia Major, Thalassemia Intermedia
Editas Medicine, Inc.
Phase 1/2
9
California, Minnesota, New York, Ohio, Pennsylvania, Tennessee
2022-04-29
Recruiting
A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Thalamotomy for the Treatment of Medication-Refractory Tremor Dominant Idiopathic Parkinson's Disease
NCT04991831Tremor Associated With Tremor Dominant Parkinson's Disease
InSightec
Observational
50
Florida, Illinois, Massachusetts, New York, North Carolina, Ohio
2022-04-28
Active, closed
STOP AF First Post-Approval Study
NCT05227053Paroxysmal Atrial Fibrillation
Medtronic Cardiac Ablation Solutions
Observational
200
Alaska, Connecticut, District of Columbia, Florida, Iowa, Massachusetts, Michigan, Ohio
2022-04-28
Active, closed
Use of the Impella BTR™ in Patients With Heart Failure: An Early Feasibility Study
NCT05291884Heart Failure, Acute Decompensated Heart Failure
Abiomed Inc.
Not applicable
10
Georgia, Illinois, Massachusetts, New Jersey, Ohio
2022-04-20
Active, closed
Study to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally for 28 Days With JYNNEOS
NCT04957485Smallpox
DrugsJynneos·Tecovirimat
SIGA Technologies
Phase 2
100
Nebraska, Ohio
2022-04-05
Active, closed
Multi-Center Study of ManNAc for GNE Myopathy
NCT04231266GNE Myopathy
Leadiant Biosciences, Inc.
Phase 2
54
California, Iowa, Kansas, Maryland, Massachusetts, Missouri, New York, Ohio
2022-04-05
Active, closed
A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors
NCT05159700Advanced Solid Tumor, Advanced Solid Malignancies
DrugPRJ1-3024
Zhuhai Yufan Biotechnologies Co., Ltd
Phase 1
39
Colorado, Florida, Ohio, Texas, Virginia
2022-03-31
Active, closed
A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria
NCT05196035Chronic Kidney Disease, Proteinuria
DrugFinerenone
Bayer
Phase 3
219
California, Florida, Maryland, Missouri, Ohio, Oregon, Utah, Washington
2022-03-28
Active, closed
Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)
NCT05348577Prostate Cancer
DrugsCapivasertib·Docetaxel
AstraZeneca
Phase 3
1,035
Arizona, California, Colorado, Maryland, Minnesota, New Jersey, New York, Ohio
2022-03-25
Active, closed
Remote Optimization, Adjustment and Measurement for Deep Brain Stimulation
NCT05269862Parkinson Disease
Abbott Medical Devices
Not applicable
100
Arizona, California, Florida, Illinois, Indiana, Massachusetts, New Hampshire, Ohio
2022-03-24
Recruiting
Physio-Anatomy Clinical Data Collection Study
NCT05312164Coronary Stenosis
Gentuity, LLC
Observational
150
California, Florida, Georgia, Massachusetts, Minnesota, Ohio
2022-03-14
Active, closed
A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease
NCT05206773Fabry Disease
DrugVenglustat
Sanofi
Phase 3
122
Alabama, California, Florida, Georgia, New York, Ohio, Pennsylvania, Texas
2022-03-11
Recruiting
CEM-Plate and CEM-Cage First-In-Human Use Efficacy Study
NCT04883411Neck Pain, Spondylosis, Spondylosis With Myelopathy, Spondylosis With Radiculopathy
ReVivo Medical, Corp.
Not applicable
50
New Jersey, New York, Ohio
2022-03-07
Recruiting
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
NCT05091424Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
DrugsMosunetuzumab·Venclyxto·Venclexta·Tocilizumab
Hoffmann-La Roche
Phase 1
332
Minnesota, New York, Ohio, Texas, Utah
2022-03-07
Recruiting
Phase 2 Study to Assess the Safety, PK, and PD of Sonefpeglutide (HM15912) in SBS-IF Subjects
NCT04775706Short Bowel Syndrome
Hanmi Pharmaceutical Company Limited
Phase 2
18
Massachusetts, Ohio
2022-03-03
Recruiting
Trisol System EFS Study
NCT04905017Tricuspid Regurgitation
Trisol Medical
Not applicable
30
California, Georgia, New York, Ohio, Pennsylvania, Tennessee, Virginia
2022-03-02
Recruiting
Inappropriate Sinus Tachycardia Registry
NCT05107635Inappropriate Sinus Tachycardia, Postural Tachycardia Syndrome
AtriCure, Inc.
Observational
500
California, Florida, Kansas, Maryland, Ohio, Texas, Utah, Washington
2022-03-01
Recruiting
MTX-001 for the Treatment of Non-Healing Venous Stasis Ulcers
NCT04647240Venous Stasis Ulcer, Venous Leg Ulcer
Merakris Therapeutics
Phase 2
80
Arizona, California, Florida, Louisiana, New York, Ohio, Texas, Virginia
2022-02-26
Active, closed
A Study to Evaluate ERAS-801 in Patients With Recurrent Glioblastoma (THUNDERBBOLT-1)
NCT05222802Glioblastoma Multiforme
Katmai Pharmaceuticals Inc.
Phase 1
52
California, Florida, Massachusetts, Michigan, New York, Ohio, Tennessee, Utah
2022-02-25
Recruiting
Safety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant
NCT05027906Prevention of Rejection in Kidney Transplant
DrugTegoprubart
Eledon Pharmaceuticals
Phase 1/2
48
Ohio
2022-02-18
Recruiting
US Post-Market Surveillance Study of the Surfacer System
NCT05050799Venous Disease
Merit Medical Systems, Inc.
Observational
30
Arizona, Florida, Georgia, Ohio, Texas, Utah, Virginia
2022-02-08
Active, closed
Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to <7 Years With NF1-related Symptomatic, Inoperable PN
NCT05309668Neurofibromatosis Type 1
DrugSelumetinib
AstraZeneca
Phase 1/2
36
Ohio, Pennsylvania, Texas, Virginia
2022-01-21
Active, closed
ADH1 and ADH2 Disease Monitoring Study (DMS)
NCT05227287Autosomal Dominant Hypocalcemia
Calcilytix Therapeutics, Inc., a BridgeBio company
Observational
95
California, Colorado, Florida, Indiana, Massachusetts, Minnesota, North Carolina, Ohio
2022-01-20
Recruiting
Pelvic Health Electrically Evoked Recording (PEER) 2 Study
NCT05200923Overactive Bladder, Fecal Incontinence, Urinary Retention
MedtronicNeuro
Not applicable
300
Indiana, Louisiana, Minnesota, Ohio, Texas
2022-01-18
Active, closed
An Efficacy and Safety Study of Basimglurant (NOE-101) in Patients With Trigeminal Neuralgia.
NCT05217628Trigeminal Neuralgia
Noema Pharma AG
Phase 2/3
166
California, Florida, Georgia, Massachusetts, Nevada, New York, Ohio
2022-01-11
Active, closed
A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
NCT05081609Advanced Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor, Platinum-resistant Ovarian Cancer
DrugsAdo-trastuzumab emtansine·Trastuzumab emtansine·Trastuzumab·Pembrolizumab
Ascendis Pharma Oncology Division A/S
Phase 1/2
320
California, Illinois, Kentucky, Massachusetts, New Jersey, New York, North Carolina, Ohio
2022-01-11
Recruiting
Single and Multiple Dose Escalation of PHIN-214 in Child-Pugh A and B Liver Cirrhotics
NCT05490888Cirrhosis, Liver, Liver Fibrosis, Ascites Hepatic
PharmaIN
Phase 1
74
Arizona, California, Louisiana, Minnesota, Ohio, Pennsylvania, Texas
2022-01-03
Recruiting
Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia
NCT04925479Myeloid Leukemia, Philadelphia Positive
DrugABL001
Novartis Pharmaceuticals
Phase 1/2
34
Indiana, Massachusetts, Mississippi, New York, Ohio, Pennsylvania, Texas, Utah
2021-12-27
Active, closed
Phase 2a Multiple Ascending Dose Study in Hospitalized Patients With Pneumonia.
NCT05123755Acute Respiratory Distress Syndrome, Viral or Bacterial Infections, Pneumonia, Pneumonia, Viral
Vasomune Therapeutics, Inc.
Phase 2
60
California, Colorado, Illinois, Maryland, Michigan, Ohio
2021-12-20
Active, closed
A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis
NCT05070858Generalized Myasthenia Gravis
DrugsCemdisiran·Pozelimab
Regeneron Pharmaceuticals
Phase 3
288
Arizona, California, Colorado, Florida, Illinois, Michigan, Ohio, Pennsylvania
2021-12-14
Active, closed
BONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxaluria Type 1 (PH1)
NCT04982393Primary Hyperoxaluria Type 1
Alnylam Pharmaceuticals
Observational
207
Arizona, District of Columbia, Massachusetts, Minnesota, Ohio, Pennsylvania, Texas
2021-12-13
Active, closed
A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations
NCT05163028Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Solid Tumor
HUYABIO International, LLC.
Phase 1
42
California, Florida, Ohio, Texas, Virginia
2021-12-13
Active, closed
Prospective Case Collection Study for New Mammography Technologies
NCT05199701Mammography
Hologic, Inc.
Not applicable
7,500
Arizona, Florida, Kentucky, Maryland, Michigan, New York, North Carolina, Ohio
2021-12-10
Active, closed
Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases
NCT05034497Leptomeningeal Metastasis
DrugRhenium Liposome Treatment
Cerenome
Phase 1
18
Illinois, New York, Ohio, Texas
2021-12-06
By invitation
Extension Study of Infigratinib in Children With Achondroplasia (ACH)
NCT05145010Achondroplasia
DrugInfigratinib
QED Therapeutics, a BridgeBio company
Phase 2
300
California, Colorado, Delaware, Maryland, Missouri, Ohio, Tennessee, Wisconsin
2021-12-06
Active, closed
Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects
NCT05172726Plaque Psoriasis
DrugTapinarof
Organon and Co
Phase 3
58
Arkansas, California, Florida, Illinois, Indiana, Ohio, Oregon, Washington
2021-12-02
Recruiting
A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
NCT05164172Migraine
DrugEptinezumab
H. Lundbeck A/S
Phase 3
600
Connecticut, Florida, Kentucky, Maryland, Michigan, New York, North Carolina, Ohio
2021-12-01
Rows per page Showing 501–1000 of 1263
Previous 1 2 3 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 6 October 2026. https://priyalifescience.com/clinical-trials-usa/state/ohio?page=2

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,118 studies in total at the last sync on 06 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,263 of those studies with a site in Ohio.

How many clinical trials are recruiting in Ohio?

737 of the 1,263 studies on this page are recruiting new participants as of the 06 Oct 2026, 03:16 UTC sync. A further 32 have not yet opened recruitment, 450 are active but closed to new participants, and 44 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.